



HAL
open science

Divalent cations influence the dimerization mode of murine S100A9 protein by modulating its disulfide bond pattern

Luca Signor, Theo Paris, Caroline Mas, Adrien Picard, Georges Lutfalla, Elisabetta Boeri Erba, Laure Yatime

► To cite this version:

Luca Signor, Theo Paris, Caroline Mas, Adrien Picard, Georges Lutfalla, et al.. Divalent cations influence the dimerization mode of murine S100A9 protein by modulating its disulfide bond pattern. *Journal of Structural Biology*, 2021, 213 (1), pp.107689. 10.1016/j.jsb.2020.107689 . hal-03120644

HAL Id: hal-03120644

<https://hal.science/hal-03120644v1>

Submitted on 7 Oct 2021

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

1 **Divalent cations influence the dimerization mode of murine S100A9 protein by**
2 **modulating its disulfide bond pattern**

3
4 **Author names**

5 Luca Signor¹, Theo Paris², Caroline Mas³, Adrien Picard², Georges Lutfalla², Elisabetta Boeri
6 Erba^{1,*}, Laure Yatime^{4,*}

7 **Author affiliations**

8 ¹ Univ. Grenoble Alpes, CEA, CNRS, IBS, F-38000 Grenoble, France

9 ² LPHI UMR5235, Univ. Montpellier, CNRS, F-34095 Montpellier, France

10 ³ ISBG UMS 3518, CNRS, CEA, Univ. Grenoble Alpes, EMBL, F-38000 Grenoble, France

11 ⁴ LPHI UMR5235, Univ. Montpellier, CNRS, INSERM, F-34095 Montpellier, France

12

13 *** Correspondence to:**

14 Dr. Laure Yatime; laure.yatime@inserm.fr or Dr. Elisabetta Boeri Erba; [elisabetta.boeri-](mailto:elisabetta.boeri-erba@ibs.fr)
15 erba@ibs.fr

16

17 **Highlights**

18 The crystallographic structure of mS100A9 bound to calcium and zinc is reported

19 A novel Zn-binding site and a disulfide bridge rigidify mS100A9 C-terminus

20 In solution, mS100A9 exists both as non-covalent and disulfide-crosslinked homodimers

21 Divalent cations modulate the relative proportion of the different mS100A9 homodimers

22 **Abstract**

23 S100A9, with its congener S100A8, belongs to the S100 family of calcium-binding proteins found
24 exclusively in vertebrates. These two proteins are major constituents of neutrophils. In response to
25 a pathological condition, they can be released extracellularly and become alarmins that induce both
26 pro- and anti-inflammatory signals, through specific cell surface receptors. They also act as
27 antimicrobial agents, mainly as a S100A8/A9 heterocomplex, through metal sequestration. The
28 mechanisms whereby divalent cations modulate the extracellular functions of S100A8 and S100A9
29 are still unclear. Importantly, it has been proposed that these ions may affect both the ternary and
30 quaternary structure of these proteins, thereby influencing their physiological properties. In the
31 present study, we report the crystal structures of WT and C80A murine S100A9 (mS100A9),
32 determined at 1.45 and 2.35 Å resolution, respectively, in the presence of calcium and zinc. These
33 structures reveal a canonical homodimeric form for the protein. They also unravel an
34 intramolecular disulfide bridge that stabilizes the C-terminal tail in a rigid conformation, thus
35 shaping a second Zn-binding site per S100A9 protomer. In solution, mS100A9 apparently binds
36 only two zinc ions per homodimer, with an affinity in the micromolar range, and aggregates in the
37 presence of excess zinc. Using mass spectrometry, we demonstrate that mS100A9 can form both
38 non-covalent and covalent homodimers with distinct disulfide bond patterns. Interestingly,
39 calcium and zinc seem to affect differentially the relative proportion of these forms. We discuss
40 how the metal-dependent interconversion between mS100A9 homodimers may explain the
41 versatility of physiological functions attributed to the protein.

42

43 **Keywords**

44 S100 proteins; divalent cations; disulfide bridges; X-ray crystallography; mass spectrometry.

45 **Abbreviations**

46 alk: alkylation; ACN: acetonitrile; DTT: dithiothreitol; HPLC: high performance liquid
47 chromatography; IAA: iodoacetamide; hS100A9: human S100A9; ICP-MS: Inductively-coupled
48 plasma mass spectrometry; LC/ESI-TOF-MS: liquid chromatography/electrospray ionization
49 time-of-flight mass spectrometry; MPD: 2-Methyl-2,4-pentanediol; MR: molecular replacement;
50 mS100A9: murine S100A9; RAGE: receptor for advanced glycation end-products; r.m.s.d.: root
51 mean square deviation; SEC: size exclusion chromatography; TFA: trifluoroacetic acid; TLR:
52 Toll-like receptor; WT: wild-type.

53

54

55

56

57

58

59

60

61

62

63

64

65

66 **1. Introduction**

67 S100 proteins are a group of small Ca^{2+} -binding proteins expressed exclusively in vertebrates
68 (Marenholz et al., 2004; Donato et al., 2013; Gonzalez et al., 2020). Several members of this family
69 also exist extracellularly where they act as alarmins and thereby play a crucial role in the
70 modulation of inflammatory responses in various disease contexts, through their interactions with
71 cell surface receptors such as the receptor for advanced glycation end-products (RAGE), Toll-like
72 receptors (TLRs) or various cluster of differentiation molecules (Leclerc et al., 2011; Roh et al.,
73 2018; Gonzalez et al., 2020).

74 S100A9, also known as calgranulin B or migration inhibitory factor-related protein 14 (MRP14), is
75 one of the most well-studied members among this large family of proteins encoded by up to thirty
76 genes (Kraemer et al., 2008; Gonzalez et al., 2020). *In vivo*, S100A9 is mostly present as a
77 heterodimer with its congener S100A8 (aka calgranulin A or MRP8) (Longbottom et al., 1992). The
78 extracellular form of this heterodimer is known as calprotectin. Homodimers of both proteins are
79 also detected to some extent, but they seem to be much less stable than the heterodimeric form
80 (Hunter et al., 1998; Kallberg et al., 2018; Wang et al., 2018b; Giudice et al., 2019). S100A8 and
81 S100A9 are highly expressed in circulating neutrophils, as well as in monocytes (Lagasse et al.,
82 1992; Striz et al., 2004). They can constitute up to 45% of the total cytosolic pool of proteins in these
83 cells, being found either in the cytoplasm or associated with the plasma membrane (Striz et al., 2004;
84 Wang et al., 2018b). Intracellularly, S100A8/A9 act as Ca^{2+} -sensors. In response to an increase in
85 calcium levels, they regulate various processes including cytoskeleton rearrangement, cell migration,
86 phagocytosis, exocytosis, and respiratory burst, the latter through the delivery of arachidonic acid to
87 the membrane-bound NADPH oxidase (Goebeler et al., 1995; Kerkhoff et al., 2005; Wang et al.,
88 2018b). In a pathological context, S100A8/A9 can be released in the extracellular space by

89 infiltrating leukocytes or following cell necrosis. Once these S100 proteins are outside the cells, their
90 functions change dramatically: they mainly act as damage-associated molecular patterns (DAMPs),
91 promoting leukocyte recruitment through chemotaxis and massive production of pro-inflammatory
92 cytokines via their interactions with specific cell surface receptors. These processes participate in the
93 maintenance of a high inflammatory state which aggravates the underlying pathology that led to
94 S100 protein release (Wang et al., 2018b; Gonzalez et al., 2020). S100A8 and S100A9 have been
95 shown to bind to both RAGE, TLR4, CD147, and neuropilin (Sakaguchi et al., 2016; Ma et al.,
96 2017). Many other yet unraveled receptors may also serve as transducers of the pro-inflammatory
97 signals elicited by the extracellular heterodimer and/or homodimers (Tomonobu et al., 2020).
98 S100A8/A9 signaling has been linked to a plethora of inflammatory or inflammation-driven
99 pathologies, including rheumatoid arthritis, myocardial infarction, Alzheimer's disease or cancers
100 (Shabani et al., 2018; Wang et al., 2018a; Marinkovic et al., 2019; Wang et al., 2019). These two
101 S100 proteins are therefore considered as valuable therapeutic targets (Bjork et al., 2009; Reeb et al.,
102 2015; Pruenster et al., 2016). They are also utilized as biomarkers for the diagnostic of certain
103 pathologies such as inflammatory bowel diseases, due to their increased plasma levels in an
104 inflammatory context (Chaabouni et al., 2016).

105 S100 proteins fold into a four-helix globular domain that is sometimes followed by a C-terminal,
106 unstructured extension of variable length (Donato et al., 2013). The minimal functional unit is a
107 homo- or heterodimer, but higher order oligomers are also encountered (Leukert et al., 2006). As for
108 other S100 proteins, S100A9 active conformation requires the presence of two Ca^{2+} ions, one in each
109 EF-hand motif, for proper effector binding (Vogl et al., 2006). In addition to calcium, both human
110 and murine S100A9 were shown to bind zinc (Raftery et al., 1996). Many S100 proteins possess two
111 symmetrical Zn^{2+} binding motifs located at the interface between the two subunits of the S100

112 homodimer (Brodersen et al., 1999; Moroz et al., 2009a; Lin et al., 2016). These tetrahedral binding
113 sites are formed by two histidine residues (or possibly an aspartic acid replacing the second His)
114 surrounding the first EF-hand motif of one protomer, and two histidine residues (or equivalent
115 positively charged residues) placed at the C-terminal end of the fourth helix in the second protomer.
116 S100 proteins can also chelate other divalent cations such as manganese, iron, nickel or copper
117 (Nakashige et al., 2015; Zackular et al., 2015; Gilston et al., 2016; Nakashige et al., 2017). Chelation
118 of Mn^{2+} , Ni^{2+} and Fe^{2+} by S100A8/A9 is part of a sequestration process known as nutritional
119 immunity that aims at depriving invading pathogens from these essential nutrients (Damo et al.,
120 2013; Nakashige et al., 2015; Nakashige et al., 2017). Thanks to the patch of histidine residues
121 located in the long, flexible C-terminal tail of its S100A9 moiety, the S100A8/A9 heterodimer can
122 generate an octahedral His_6 binding motif for Mn^{2+}/Ni^{2+} coordination, thereby increasing the affinity
123 of the protein for these metal ions (Damo et al., 2013; Nakashige et al., 2018). Therefore,
124 S100A8/A9 is considered as a potent antimicrobial peptide (Corbin et al., 2008). Other S100 proteins
125 have been shown to possess bactericidal properties (Glaser et al., 2005; Realegeno et al., 2016), but
126 it is not known whether S100A9 also displays such ability to kill bacteria outside the S100A8/A9
127 heterodimer (i.e. as a homodimer).

128 Metal ion chelation by S100 proteins may however not be restricted to an antimicrobial activity.
129 Indeed, divalent cations other than calcium may act as modulators of the biological function of S100
130 proteins, in particular zinc (Baudier et al., 1986; Nakatani et al., 2005; Moroz et al., 2011). Various
131 processes may induce modifications in the structural organization of S100 proteins, including ion
132 binding, which promotes protein oligomerization, as well as post-translational modifications and/or
133 oxidation-dependent mechanisms that may lead for example to the formation of disulfide-
134 crosslinked S100 oligomers having distinct functions than the non-covalent assemblies

135 (Winningham-Major et al., 1989; Haase-Kohn et al., 2011; Lim et al., 2011; Unno et al., 2011;
136 Yatime, 2017). We and others have proposed that these effects may be the direct translation of a
137 change in S100 proteins tertiary and/or quaternary structure (Moroz et al., 2009b; Yatime et al.,
138 2016). Although these ideas are generally more and more well perceived by the scientific community
139 working in the field, these forms have so far not been characterized in details. To date, only one
140 structural study reports the finding of a novel homodimeric form of S100 proteins, observed for
141 S100A6 in its complex with RAGE and stabilized by zinc and cysteine-dependent mechanisms
142 (Yatime et al., 2016). In order to understand how these proteins can have many diverse and
143 sometimes contradictory functions, differences between species should also be taken into account.
144 For example, the C-terminal region of murine S100A9 (mS100A9) was shown to have
145 antinociceptive functions and to inhibit macrophage functions through modulation of B1 cell
146 function (Paccola et al., 2008; Pagano et al., 2014). Remarkably, these properties have so far not
147 been ascribed to the human protein. Such distinct properties may arise from local differences in
148 the 3D-architectures of human and murine proteins, possibly driven by divalent cations since
149 S100A9 C-terminal region has been involved in metal chelation, at least as part of the S100A8/A9
150 heterocomplex (Damo et al., 2013; Nakashige et al., 2015).

151 In order to gain deeper insight on how divalent cations may act as regulators of these processes at
152 a structural level, we have undertaken the biophysical characterization of mS100A9 in the presence
153 of various sets of cations. Using X-ray crystallography and mass spectrometry, we show that the
154 mS100A9 homodimers exist, in solution, both as non-covalent and covalent, disulfide-crosslinked
155 forms. The non-covalent homodimers contain an intramolecular disulfide bridge linking Cys91 to
156 Cys111. The disulfide-crosslinked homodimers are characterized by distinct disulfide bond
157 patterns depending on the metal present. We also demonstrate that the relative proportion of these

158 forms depends on the ions bound to the protein. Calcium appears to promote the non-covalent,
159 canonical homodimer, whereas zinc enhances the formation of the SS-bridged homodimer(s).
160 Furthermore, we observe that the C-terminal region of mS100A9 contains an additional Zn²⁺
161 binding site, distinct from the one at the interface between the two monomers that is generally
162 observed in the canonical S100 homodimers. Finally, we provide isothermal titration calorimetry
163 (ITC) analyses of zinc binding to mS100A9 and dynamic light scattering (DLS) studies of the
164 zinc-dependent aggregation of mS100A9. All these findings suggest that divalent cations may
165 drastically affect the local conformation of mS100A9 C-terminal tail. In the present study, we
166 discuss the possible consequences of these structural modulations in terms of physiological
167 function.

168 **2. Material and Methods**

169 ***2.1. Expression and purification of mS100A9 WT and mutant proteins***

170 The gene coding for WT mS100A9, optimized for codon usage in *E. coli*, was synthesized by
171 Genscript and further cloned into the *NcoI* – *HindIII* fragment of vector pETM11 (EMBL vector
172 collection). The protein sequence of the mS100A9 sample obtained with this construct after
173 purification is indicated in Supplementary Table S1. A theoretical molecular weight of 13177 Da
174 is expected. Cysteine-to-alanine point mutants C80A, C91A and C111A, were obtained by PCR-
175 based site-directed mutagenesis using High Fidelity Hot Start Phusion DNA Polymerase
176 (Finnzymes) and anti-complementary oligonucleotides bearing the mutation to introduce
177 (Supplementary Table S1). The resulting mS100A9:pETM11 constructs were used to transform
178 *E. coli* BL21 (DE3) cells. Protein expression and purification was carried out as described
179 previously (Yatime, 2019). Transformed cells were grown at 37°C for 4 hours and protein
180 expression was induced overnight at 18°C by adding 1 mM IPTG in the culture medium. Cells

181 were harvested by centrifugation at 6000 g and disrupted by sonication. After clarification by
182 centrifugation, the cell lysate was loaded onto a 5 ml HisTrap Ni-column (GE Healthcare)
183 equilibrated with 50 mM Tris-HCl pH 7.5, 300 mM NaCl, 30 mM imidazole, 1 mM PMSF.
184 Following high salt wash with a buffer containing 1 M NaCl, to remove nonspecifically bound
185 contaminants, the protein of interest was eluted with a buffer containing 500 mM imidazole. The
186 N-terminal polyhistidine tag was then removed overnight by incubating the sample at 4°C with
187 home-made recombinant Tobacco Etch Virus protease (rTEV), using a protein to rTEV massic
188 ratio of 30 to 1. A second step of affinity chromatography on the His-Trap Ni-column was then
189 performed to separate the cleaved mS100A9 protein, eluting in the flow-through, from the His₆-
190 tag and His-tagged rTEV that remained bound to the column. 10 mM EDTA/EGTA were then
191 added to the sample to remove all traces of divalent cations and, after overnight incubation with
192 the chelating agents, the protein was further purified by size exclusion chromatography (SEC) on
193 a 24 ml Superdex 75 Increase column (GE Healthcare) equilibrated with Buffer 1 (20 mM Tris-
194 HCl pH 7.5, 100 mM NaCl). Fractions corresponding to the dimeric form of mS100A9 were
195 pooled and the purity of the sample was verified by SDS-PAGE (Supplementary Fig. S1A). The
196 purified mS100A9 homodimer was flash frozen in liquid nitrogen and stored at -80°C until use.
197 This purification protocol yielded in routine 10 mg of pure mS100A9 homodimer per liter of
198 culture.

199 Before biophysical analyses, mS100A9 samples (WT and mutants) were freshly repurified on a
200 Superdex 75 Increase SEC column equilibrated with Buffer 1, to ensure that a homogenous dimeric
201 form of the protein was used (Supplementary Fig. S1B). SEC was performed at 18°C, at a flow
202 rate of 0.4 ml/min. 2.5 mg of mS100A9 dimeric pool were injected per run (loading volume: 400
203 µl of protein concentrated at 6.2 mg/ml). After pooling again the dimeric peak of mS100A9 and

204 concentrating, the different samples were prepared by incubating mS100A9 at a final protein
205 concentration of 4.8 mg/ml (365 μ M) with either 1 mM CaCl₂ (mS100A9 + Ca), 1 mM ZnCl₂
206 (mS100A9 + Zn) or 1 mM CaCl₂ + 1 mM ZnCl₂ (mS100A9 + Ca/Zn), while the apo mS100A9
207 sample did not contain any of these metals (as assessed by ICP-MS, Table 3). To prepare samples
208 for MS analysis, these stock solutions were further diluted to a final mS100A9 concentration of
209 50 μ M.

210 **2.2. Crystallization, data collection and refinement**

211 Initial crystallization screening was performed by hand using the sitting-drop vapor diffusion
212 technique at 18°C in 96-well Swissci MRC crystallization plates and commercial screens from
213 Molecular Dimensions Ltd. mS100A9 (WT and C80A) crystallized at 10 mg/ml (760 μ M) in the
214 presence of 5 mM CaCl₂ (6.6 eq) / 2 mM ZnCl₂ (2.6 eq) over a reservoir containing 0.2 M
215 Ammonium sulfate, 4 mM spermine tetrahydrochloride, 50 mM Bis-Tris pH 7.0, 45% MPD.
216 Crystals were directly flash frozen in liquid nitrogen and all datasets (native and anomalous) were
217 collected at 100K on beamline ID23eh1 at ESRF (Grenoble, France) or beamline X06DA at SLS
218 (Villingen, Switzerland). Datasets were processed with XDS (Kabsch, 2010) and the structure was
219 determined by molecular replacement (MR) in PHASER (McCoy et al., 2007), using the structure
220 of Ca²⁺-bound human S100A9 (PDB_ID 1IRJ) (Itou et al., 2002) for the WT protein, and the newly
221 determined structure of WT mS100A9 for the C80A mutant. Refinement of the models was carried
222 out by alternating cycles of manual rebuilding in COOT (Emsley et al., 2004) and cycles of energy
223 minimization in PHENIX.REFINE (Adams et al., 2010) including refinement of individual
224 isotropic Atomic Displacement Parameters (ADP) using Translation–Libration–Screw (TLS)
225 parameterization (Table 1 and Supplementary Table S2). The quality of the final models was

226 assessed with MOLPROBITY (Davis et al., 2007). All figures were made with the Pymol
227 Molecular Graphics System (version 0.99rc6, DeLano Scientific LLC).

228 ***2.3. Inductively-coupled plasma mass spectrometry (ICP-MS)***

229 The metal content of our protein preparation of WT mS100A9 was analyzed by ICP-MS prior to
230 cation binding studies. A 200 μ M stock solution of WT mS100A9 in Buffer 1 was used for
231 measurements. Trace element concentrations were determined both in Buffer 1 alone and in the
232 mS100A9 sample, with the Thermo Scientific iCAP TQ ICP-MS system (using the Kinetic Energy
233 Discrimination mode and He as collision gas) on the AETE-ISO platform (OSU OREME,
234 University of Montpellier, France). An internal solution, containing Be, Sc, Ge, Rh was added on-
235 line to the samples to correct signal drifts. Certified water SLRS-6 (National Research Council of
236 Canada, Metrology Research Centre) was used as a control of the correctness of the measurements.

237 ***2.4. Isothermal titration calorimetry (ITC)***

238 The affinity of mS100A9 for ZnCl_2 in the presence or absence of CaCl_2 was determined using a
239 MicroCal iTC200 system (Malvern Panalytical, Malvern, UK). Experiments were performed at
240 25°C in 20 mM Tris-HCl pH 7.5, 100 mM NaCl, +/- 1 mM CaCl_2 . The mS100A9 protein solution
241 (at concentrations ranging from 30 μ M to 120 μ M) was loaded in the calorimetric cell. ZnCl_2 (at
242 concentrations ranging between 0.6 and 1.2 mM) was titrated in the protein sample typically by
243 performing 16 injections of 2.5 μ L or 20 injections of 2 μ L each. The dissociation constant (K_d),
244 enthalpy of binding (ΔH), and stoichiometry (N) were obtained after fitting the integrated and
245 normalized data to a single-site binding model. The data were processed using Origin 7.0 (Malvern

246 Panalytical, Malvern, UK). All experiments were performed at least in duplicate to check for
247 reproducibility of the data.

248 **2.5. Dynamic light scattering (DLS)**

249 DLS measurements were performed at 20°C using a Zetasizer Nano S from Malvern Instruments
250 Ltd using a quartz cuvette from Hellma Analytics. We measured the hydrodynamic radius (Rh) of
251 the protein mS100A9 at 120 µM, in the presence or absence of 1 mM CaCl₂, at different mS100A9
252 to ZnCl₂ molar ratios (1:0, 1:1, 1:2, 1:3 and 1:4).

253 **2.6. Liquid chromatography/electrospray-ionization mass spectrometry (LC/ESI-TOF-MS)**

254 The disulfide bond pattern of mS100A9 in the presence or absence of different divalent cations
255 was investigated by Liquid Chromatography/Electrospray Ionization Mass Spectrometry (LC/ESI-
256 TOF-MS) on a 6210 TOF mass spectrometer coupled to a HPLC system (1100 series, Agilent
257 Technologies). The mass spectrometer was calibrated with tuning mix (ESI-L, Agilent
258 Technologies). The following instrumental settings were used: gas temperature (nitrogen) 300 °C,
259 drying gas (nitrogen) 7 L min⁻¹, nebulizer gas (nitrogen) 10 psig, V_{cap} 4 kV, fragmentor 250 V,
260 skimmer 60 V, V_{pp} (octopole RF) 250 V. The HPLC mobile phases were prepared with HPLC
261 grade solvents. Mobile phase A composition was: H₂O 95%, ACN 5%, TFA 0.03%. Mobile phase
262 B composition was: ACN 95%, H₂O 5%, TFA 0.03%.

263 For MS analysis of the intact protein, three different samples were prepared for each set of ions:
264 1) *no treatment*: the protein sample at 10 µM concentration in the corresponding buffer, without
265 any chemical treatment; 2) *alkylation (IAA)*: the protein sample at 10 µM concentration, after
266 incubation with 55 mM IAA (30 min at room temperature, in the dark); 3) *reduction and alkylation*
267 *(DTT+IAA)*: the protein sample at 10 µM concentration, first incubated with 10 mM DTT (45 min
268 at 56°C, under gentle mixing) followed by treatment with 55 mM IAA (30 min at room

269 temperature, in the dark). For the mS100A9 protein without ions, a fourth sample was prepared:
270 4) *unfolding, reduction and alkylation (urea+DTT+IAA)*: the protein sample at 10 μ M
271 concentration, first incubated with 10 mM DTT in the presence of 8 M urea (45 min at 56°C, under
272 gentle mixing) followed by treatment with 55 mM IAA (30 min at room temperature, in the dark).
273 2 μ l of each protein sample (20 pmol) were injected for MS analysis and were first desalted on-
274 line for 3 min with 100% of mobile phase A (flow rate of 50 μ l/min), using a C8 reverse phase
275 micro-column (Zorbax 300SB-C8, 5 μ m, 5 \times 0.3 mm, Agilent Technologies). The sample was then
276 eluted with 70% of mobile phase B (flow rate of 50 μ l/min) and MS spectra were acquired in the
277 positive ion mode in the 300-3000 m/z range. Data were processed with MassHunter software (v.
278 B.02.00, Agilent Technologies) and GPMAW software (v. 7.00b2, Lighthouse Data, Denmark).
279 The mass accuracy on the experimental mass values obtained for the mS100A9 samples from ESI
280 mass spectra, after deconvolution, was of \pm 0.06 Da (for the “monomeric” peak) and of \pm 0.2 Da
281 (for the “dimeric” peak). To verify whether monomeric and dimeric species have similar relative
282 ionization efficiencies, we assessed the relative ionization efficiency of mS100A9 mutants C111A
283 (that gives only monomeric species) and C91A (that gives only dimeric species). The results,
284 displayed in Supplementary Figure S9, show that both species have relatively similar ionization
285 efficiencies with an estimated average percent error of 5% max, which we consider acceptable.
286 Based on these results, we then evaluated the relative proportions of monomeric and dimeric
287 species in our LC/ESI-TOF MS experiments by measuring the peak area of each species in the
288 deconvoluted ESI MS spectra and reporting their values as a percentage of the sum of all species
289 observed (area % of deconvoluted peak) (see for ex. Figures 4A and 5A). The number of disulfide
290 bonds versus free cysteines was determined for each set of ions by comparing the ESI MS spectra

291 recorded for the samples without any chemical treatment, with those after reaction with IAA alone
292 or DTT + IAA.

293 ***2.7. Native mass spectrometry***

294 The samples were analyzed by native mass spectrometry (Boeri Erba et al., 2015; Boeri Erba et
295 al., 2018; Boeri Erba et al., 2020). Protein ions were generated using a nanoflow electrospray
296 (nano-ESI) source. Nanoflow platinum-coated borosilicate electrospray capillaries were bought
297 from Thermo Electron SAS (Courtaboeuf, France). MS analyses were carried out on a quadrupole
298 time-of-flight mass spectrometer (Q-TOF Ultima, Waters Corporation, Manchester, U.K.). The
299 instrument was modified for the detection of high masses (Sobott et al., 2002; van den Heuvel et
300 al., 2006). The following instrumental parameters were used: capillary voltage = 1.2-1.3 kV, cone
301 potential = 40 V, RF lens-1 potential = 40 V, RF lens-2 potential = 1 V, aperture-1 potential = 0
302 V, collision energy = 30-140 V, and microchannel plate (MCP) = 1900 V. All mass spectra were
303 calibrated externally using a solution of cesium iodide (6 mg/mL in 50% isopropanol) and were
304 processed with the Masslynx 4.0 software (Waters Corporation, Manchester, U.K.) and with
305 Massign software package (Morgner et al., 2012).

306 **3. Results**

307 ***3.1. General overview of the Ca²⁺/Zn²⁺-bound mS100A9 structure***

308 To date, no structural data on mS100A9 are available. Quite a few structures of hS100A9 are
309 deposited in the Protein Data Bank (PDB), either for the homodimeric form of the protein or for
310 the S100A8/A9 heterotetramer (Itou et al., 2002; Korndorfer et al., 2007; Chang et al., 2016).
311 However, none of these structures has been obtained in the presence of zinc. In fact, the sole
312 information that may be derived on zinc chelation by S100A9 arise from the structures of
313 manganese- and nickel-bound human S100A8/A9 (Damo et al., 2013; Gagnon et al., 2015;

314 Nakashige et al., 2017; Nakashige et al., 2018). No such data exist for the S100A9 homodimer,
315 although this form is able to bind zinc as well (Raftery et al., 1999). Furthermore, differences in
316 metal coordination between the human and murine proteins cannot be excluded. We therefore
317 started investigating zinc binding to mS100A9 from a structural point of view. As for hS100A9,
318 mS100A9 tends to form higher oligomers than just simple homodimers, as we indeed observed
319 when we analyzed the concentrated protein by size exclusion chromatography (SEC)
320 (Supplementary Figs. S1A and S1C-D). To avoid adding a level of complexity to the study, we
321 focused our experiments on the dimeric pool of the protein, collected separately from the SEC
322 column and rerun after long term storage at -80°C on the same column to evaluate its stability
323 (Supplementary Fig. S1B). Despite extensive efforts, we could only obtain crystals of the protein
324 in the presence of calcium and zinc. No crystals appeared if any of the two ions was absent from
325 the protein buffer. The crystals belonged to space group C2 and diffracted to a maximum resolution
326 of 1.45 Å (Table 1). The structure was determined by molecular replacement using calcium-bound
327 hS100A9 (Itou et al., 2002) as the MR search model.

328 The final refined atomic model for Ca²⁺/Zn²⁺-bound mS100A9 is displayed in Figure 1A (Table 1
329 for data statistics). Quality of the fit between this model and the experimental electron density map
330 can be assessed in Figure 1B. As expected, mS100A9 arranges in a centro-symmetrical homodimer
331 that corresponds to the canonical dimer reported for all other S100 proteins. Both subunits bind
332 two calcium ions, in the two EF-hand motifs, and more surprisingly, two zinc ions, one at the
333 interface between the two subunits and one within the C-terminal tail. The exact nature of these
334 ions was confirmed by calculating anomalous difference Fourier maps from datasets collected at
335 the Zn peak (wavelength of 1.27 Å), where both Zn and Ca display anomalous scattering of X-

336 rays, and just after the Zn peak (wavelength of 1.30 Å), where Zn anomalous signal is lost whereas
337 calcium anomalous signal increases (Fig. 1C).

338 The overall architecture of mS100A9 closely resembles that of hS100A9. As depicted in Figure
339 1D, the mS100A9 protomer (beige) superimposes quite well with the corresponding Ca²⁺-bound
340 protomer of both WT (blue) and C3S (red) hS100A9 homodimer (Itou et al., 2002; Chang et al.,
341 2016) as well as with the Ca²⁺/Mn²⁺-bound hS100A9 moiety (grey) of the hS100A8/A9
342 heterocomplex (Damo et al., 2013). An overall r.m.s.d. on C α atoms of 1.05 and 1.42 Å can be
343 measured between the murine protein and the WT or mutated hS100A9, respectively, for the core
344 region encompassing helices H1 to H4 (Fig. 1D). Similarly, r.m.s.d. values on C α atoms comprised
345 between 1.19 and 1.31 Å were obtained by comparing mS100A9 and the hS100A9 moiety from
346 the different human S100A8/A9 structures. The major movements between these structures occur
347 in the second half of helix H4 and in the C-terminal tail of the protein (Fig. 1D), a region that is
348 not modeled in all available structures due to its high flexibility. In mS100A9, the long C-terminal
349 tail adopts a rigidified architecture that will be discussed in more details below.

350 In contrast to the conserved conformation of the S100A9 protomer observed between human and
351 murine proteins, the respective position of the two mS100A9 subunits within the homodimer
352 differs quite substantially from what is observed for the Ca²⁺-bound hS100A9 homodimers (Fig.
353 1E). Indeed, subunit B of mS100A9 is shifted away from subunit A by a rotation of approximately
354 30° as compared to the equivalent subunits in both structures of the hS100A9 homodimer (Fig.
355 1E). This differential positioning of the two S100A9 subunits may reflect intrinsic differences
356 between the two S100A9 orthologues. Another possibility is that zinc binding triggers the
357 reorientation of the two S100 subunits. To address this question, we then compared the relative
358 orientation of the two S100 subunits in our Ca²⁺/Zn²⁺-bound mS100A9 homodimer with that of

359 other S100 homodimers bound to calcium alone or to calcium plus zinc. As depicted in Figure 1F
360 and Supplementary Figure S2, our mS100A9 homodimer superimposes quite well with the
361 hS100A7 (Brodersen et al., 1999), hS100A8 (Ishikawa et al., 2000; Lin et al., 2016), hS100A12
362 (Moroz et al., 2001; Moroz et al., 2003), hS100A15 (Murray et al., 2012) and hS100B (Ostendorp
363 et al., 2007; Ostendorp et al., 2011) homodimers, whether they are Ca^{2+} -bound (hS100A8,
364 hS100A12, hS100B), $\text{Ca}^{2+}/\text{Zn}^{2+}$ -bound (hS100A7, hS100A8, hS100A15, hS100B) or even
365 $\text{Ca}^{2+}/\text{Cu}^{2+}$ -bound (hS100A12). In fact, no major repositioning of the two S100 subunits is observed
366 in these different S100 homodimers upon zinc addition to the Ca^{2+} -bound form. This suggests that
367 the differential S100/S100 orientation we observe between Ca^{2+} -bound hS100A9 and $\text{Ca}^{2+}/\text{Zn}^{2+}$ -
368 bound mS100A9 is not a direct consequence of zinc binding. The fact that the hS100A9 structures
369 have been determined either by NMR (for the WT protein) or by X-ray crystallography but using
370 a hS100A9 mutant form (for the C3S mutant) may also account for the observed differences. In
371 any case, the quaternary organization of our $\text{Ca}^{2+}/\text{Zn}^{2+}$ -bound mS100A9 homodimer is very similar
372 to that of other $\text{Ca}^{2+}/\text{Zn}^{2+}$ -bound s100 homodimers.

373 ***3.2. mS100A9 harbors two distinct types of zinc binding sites***

374 To our knowledge, no biophysical characterization of zinc binding to the S100A9 homodimer has
375 been published so far, although S100A9 is known to bind zinc in the absence of its S100A8
376 congener (Bjork et al., 2009). In particular, the stoichiometry of zinc binding to the S100A9
377 homodimer and the exact nature of the cation binding sites remain unknown. Unexpectedly, our
378 structure of $\text{Ca}^{2+}/\text{Zn}^{2+}$ -bound mS100A9 revealed the presence of two Zn^{2+} ions per S100A9
379 protomer. The first binding site is positioned at the interface between the two mS100A9 subunits.
380 The mS100A9 homodimer contains two equivalent sites of this type, arranged centro-
381 symmetrically (Zn1 and Zn3 in Figure 1A) and displaying a tetrahedral geometry (Fig. 2A), with

382 average Zn-ligand bond distances between 1.9 and 2.0 Å (Table 2). The first mS100A9 subunit
383 provides two of the coordinating residues, His21 at the end of helix H1, and Asp31 within the first
384 Ca²⁺ EF-hand. The two other Zn²⁺-chelating residues, His92 and His96, come from helix H4 in
385 the second subunit. This site corresponds to the canonical His₃Asp zinc binding motif which is
386 encountered in the His-Zn class of S100 proteins, and its geometry is highly similar to that of the
387 His-Zn sites present in hS100A7 (Brodersen et al., 1999; Supplementary Fig. S3A) and hS100A12
388 (Moroz et al., 2009a; Supplementary Fig. S3B). The geometry of this site also corresponds well to
389 that of the Zn-binding sites found in hS100B (Ostendorp et al., 2011; Supplementary Figure S3C)
390 and hS100A8 (Lin et al., 2016; Supplementary Figure S3D), although in these two cases the
391 coordinating motifs are respectively His₃Glu and His₄.

392 The second Zn-binding site observed in our structure involves the three histidine residues located
393 in the C-terminal tail of mS100A9 (Fig. 2B, purple triangles). These three C-terminal His residues
394 form a novel, tetrahedral Zn²⁺-binding motif (Fig. 2C), never encountered so far in other S100
395 protein structures. The fourth coordinating residue, Glu65 at the end of helix H3, is provided by a
396 symmetry-related mS100A9 molecule within the crystal. Average Zn-ligand bond distances for
397 this second Zn-site range between 1.9 and 2.1 Å (Table 2). Due to the involvement of its three His
398 residues in zinc chelation, the C-terminal tail folds back over the mS100A9 subunit core. This
399 folding is further promoted by the presence of a disulfide bridge connecting Cys91, at the end of
400 helix H4, and Cys111 at the end of the C-terminal tail. The C-terminal tail therefore adopts a
401 rigidified architecture, forming a closed loop that protrudes at the extremity of helix H4 (Fig. 2D).
402 This novel Zn-binding site is rendered possible in mS100A9, at least in the crystal structure,
403 because the three His residues in its C-terminal portion are not placed contiguously but are instead
404 spaced by a residue of different nature, giving rise to an HxHxH motif (Fig. 2B). hS100A9 likewise

405 contains a cluster of histidine residues in its C-terminal tail (Fig. 2B, orange circles). Since no
406 structure of the hS100A9 homodimer bound to zinc is available, it is not possible to know if such
407 a site can be formed within the human homodimer. However, the structures of the human
408 S100A8/A9 heterocomplex bound to Mn^{2+} or Ni^{2+} (Damo et al., 2013; Nakashige et al., 2018)
409 revealed that in hS100A9, these C-terminal His residues participate in the coordination of the Mn^{2+}
410 ion present at the interface between the two S100 subunits, thereby generating an octahedral His_6
411 coordination site with high affinity. In the context of the S100A8/A9 heterocomplex, this non-
412 canonical His_6 site was shown to bind both Zn^{2+} , Mn^{2+} , Ni^{2+} and Fe^{2+} (Damo et al., 2013;
413 Nakashige et al., 2015; Nakashige et al., 2017). It remains unknown whether such an octahedral
414 site would also be used for zinc chelation in the context of the hS100A9 homodimer or whether
415 hS100A9 could also form a second Zn-binding site, similar to the one we observe for mS100A9.
416 Obviously, since the three terminal histidines of hS100A9 are contiguous to each other (Fig. 2B),
417 the geometrical constraint imposed on the protein backbone would only allow two of them to
418 arrange simultaneously in a tetrahedral coordination motif, and the two remaining Zn-ligand would
419 have to be provided by a distinct molecule/ion.

420 Since the novel Zn-site we observe in mS100A9 structure is promoted by crystal contacts, we
421 investigated whether it was a crystallization artifact or whether it could also exist in solution. For
422 this purpose, we first confirmed that our mS100A9 sample had been purified in the apo form by
423 quantifying the residual content of divalent cations present in our protein preparation using
424 inductively-coupled plasma mass spectrometry (ICP-MS). The measured metal/S100 ratios show
425 that there is no significant metal-ion contamination in our sample (Table 3). We then performed
426 ITC titrations of zinc binding to mS100A9, either in the absence or presence of calcium. As shown
427 in Figures 3A and 3B, the thermograms were best fitted with a single-site model, indicating that

428 mS100A9 binds one Zn^{2+} ion per subunit with an average dissociation constant (K_d) ranging
429 between 16 and 25 μM depending on the experiments. Thus, the mS100A9 homodimer possesses
430 two equivalents Zn-binding sites with affinities in the medium μM range. Differences in K_d values
431 between apo mS100A9 and Ca^{2+} -bound mS100A9 are within error range, suggesting that calcium
432 has no effect on mS100A9 affinity for zinc. A few of the titrations curves exhibited a small, second
433 phase that could indicate a biphasic binding mode but fitting with a two-sites model did not yield
434 pertinent results in these cases (data not shown). Thus, even if a second Zn-binding site exists on
435 the mS100A9 protomer in solution, we could not detect it with the experimental conditions
436 employed here. Importantly, all titrations ended up at 2 molar equivalents of zinc as compared to
437 mS100A9. When we increased further zinc concentration in the titrations, mS100A9 started
438 precipitating. To analyze this metal-dependent aggregation of mS100A9 in more details, we
439 performed DLS analysis of the sample, both in the presence and absence of calcium, using
440 increasing concentrations of zinc. As depicted in Figures 3C and 3D, zinc-dependent aggregation
441 of mS100A9 readily occurs as soon as the zinc to mS100A9 molar ratio equals or exceeds 3
442 equivalents and this phenomenon is independent of calcium. This tendency to aggregate in the
443 presence of excess zinc evidently complicates the analysis of the Zn-mS100A9 samples with native
444 MS (see below). It may also impair the detection of low affinity Zn-binding sites by ITC.

445 ***3.3. In solution, mS100A9 exists as several homodimeric forms with distinct disulfide bond***
446 ***patterns***

447 Our structure reveals that mS100A9 forms an intramolecular disulfide bridge between Cys91 and
448 Cys111, at least in the presence of high calcium and zinc concentrations. By contrast, a disulfide
449 bridge between Cys80 and Cys91 was previously reported for the protein isolated from native
450 source or produced recombinantly in the absence of divalent cations (Raftery et al., 1999).

451 Presence of divalent cations may therefore influence SS link formation within mS100A9. In
452 particular, zinc coordination at the C-terminal tail may preferentially stabilize the Cys91-Cys111
453 SS bridge (or *vice versa*). To gain more insight into the disulfide bonding pattern of wild-type
454 (WT) mS100A9, we analyzed the dimeric pool of mS100A9 under denaturing conditions using
455 LC/ESI-TOF MS (Supplementary Fig. S4). This technique enables the characterization of both
456 inter- and intramolecular disulfide crosslinks whereas all the non-covalent interactions are broken
457 (Boeri Erba et al., 2018).

458 We first analyzed WT mS100A9 in the absence of divalent cations. When all three cysteines are
459 reduced (i.e. are not engaged in an SS-bond), our mS100A9 protein has a theoretical mass of
460 13177.1 Da as a monomer, and of 26354.2 Da as a homodimer. Under denaturing conditions and
461 in the absence of DTT, WT mS100A9 generates an LC/ESI-TOF MS spectrum with one major
462 peak (Fig. 4A; mass 13175.1 Da, 66% of the total protein signal) referred to as the “monomeric”
463 peak and whose mass confirms the presence of one intramolecular disulfide bond per molecule.
464 Since the mS100A9 sample was analyzed under denaturing conditions, the “monomeric” peak is
465 composed of both native monomers and single subunits generated by the disassembly of non-
466 covalent oligomers. The ESI MS spectrum also reveals a minor peak (Fig. 4A; mass 26349.5 Da,
467 34% of the total protein signal) referred to as the “dimeric” peak. Upon reduction with DTT, the
468 “dimeric” peak almost totally disappears (Fig. 4D), confirming that the mS100A9 form(s) giving
469 rise to this peak contain intersubunit disulfide bonds.

470 To characterize the oligomeric state of these covalent and non-covalent forms of mS100A9, we
471 analyzed the same samples using native MS. In both absence and presence of DTT, mS100A9 is
472 mostly dimeric (Figs. 4B-C; mass: 26351 ± 2 Da and 26355 ± 3 Da, respectively), in agreement
473 with our SEC experiments (Supplementary Fig. S1B). A small amount of monomer is also

474 observed in both conditions (Figs. 4B-C; mass: 13175 ± 2 Da and 13177 ± 1 Da, respectively).
475 Due to the gentle experimental conditions employed, native MS is a technique that preserves non-
476 covalent interactions (Boeri Erba et al., 2020). The monomeric state we observe can therefore not
477 arise from the breaking of dimers during data acquisition. Interestingly, mS100A9 carries less
478 charges in the presence of disulfide bridges (Figs. 4B-C). This reflects the higher degree of
479 compactness of the disulfide crosslinked mS100A9 compared to the non-crosslinked one. This is
480 also in agreement with our SEC experiments which show that in the presence of DTT, the peak
481 corresponding to homodimeric mS100A9 elutes slightly earlier than under non-reducing
482 conditions (Supplementary Fig. S1B), suggesting a less compact form in the presence of DTT.
483 Addition of DTT does not yield a significantly higher proportion of monomeric mS100A9 (Fig.
484 4C), suggesting that mS100A9 remains dimeric upon breakage of the intersubunit SS bridges.

485 To assess the number of free cysteines, we treated mS100A9 with iodoacetamide (IAA), in the
486 absence or presence of DTT, and we analyzed these samples using LC/ESI-TOF MS (Figs. 4E-F).
487 Reaction with IAA increases the mass of the “monomeric” peak to 13232.1 Da (+ 57 Da),
488 indicating the covalent addition of one acetamide group per molecule (Figs. 4E, 4G). This suggests
489 that only one cysteine per mS100A9 molecule is free to react with IAA. Treatment with DTT and
490 IAA gives rise mainly to addition of 1 and 2 acetamide groups (Figs. 4F-G). Thus, DTT reduces
491 two cysteines that were previously engaged in an intramolecular disulfide bridge. Species with 3
492 acetamide groups were not detected after DTT and IAA treatment. There are several explanations:
493 one of the three cysteines may be partly inaccessible to the solvent after cleavage of the SS bridge;
494 alternatively, the reaction conditions may not be sufficient to reduce all cysteines. To address this
495 question, we incubated mS100A9 with DTT in the presence of strong denaturant (8M urea) before
496 performing alkylation with IAA using identical conditions as previously. In these conditions, we

497 obtained fully tri-alkylated protein (Fig. 4H, species at molecular mass 13348.3 Da). Thus, upon
498 complete unfolding of the protein, all three cysteines reacted with IAA.

499 Reaction with IAA increases the mass of the “dimeric” peak of 114 Da, indicating a covalent
500 addition of 2 acetamide groups per dimer (Figs. 4E, 4I). This means that only two cysteines (out
501 of six available) are free to react. We may hypothesize two intersubunit SS bonds between two
502 S100A9 protomers, forming a covalent dimer. Another possibility is that only one inter-subunit
503 SS bond bridges the two mS100A9 protomers and one of the protomers also bears an
504 intramolecular SS bridge.

505 Altogether MS data suggest that 1) WT mS100A9 forms both non-covalent and SS-crosslinked
506 homodimers (Figs. 4A-4D); 2) the protein also exists as a monomer (Figs. 4B-C); 3) the non-
507 covalent species all contain one intramolecular disulfide bridge per S100A9 subunit (Fig. 4G).

508 ***3.4. The homodimerization mode of mS100A9 is differentially affected by calcium and zinc***

509 Next, we aimed to investigate the effect of divalent cations on the mS100A9 dimeric pool. Thus,
510 we performed LC/ESI-TOF and native MS experiments on WT mS100A9 incubated in the
511 presence of calcium alone, zinc alone, or both metals (Supplementary Fig. S4). As shown in Figure
512 5, we observe the presence of both the “monomeric” and “dimeric” peaks in the LC/ESI-TOF
513 spectra regardless of the metal present. However, when zinc is present, the equilibrium is
514 significantly shifted towards the formation of SS-crosslinked homodimers (Figs. 5C, 5E).

515 In the absence of divalent cations or in the sole presence of calcium, the “monomeric” peak
516 observed under denaturing conditions is predominant (Figs. 4A, 5A). In the native MS conditions,
517 the non-covalent homodimer is in equilibrium with a monomeric form of the protein, whose
518 abundance remains low (Fig. 4B, 5B). The use of IAA shows that calcium does not affect the
519 disulfide bond pattern of the non-covalent and SS-crosslinked homodimers (Supplementary Fig.

520 S5). In the presence of calcium, the “monomeric peak” still contains an intramolecular SS bridge
521 per subunit (Supplementary Figs. S5A-C), whereas the disulfide-crosslinked homodimer has two
522 SS bonds and two free cysteines (Supplementary Fig. S5D). The addition of calcium seems only
523 to loosen slightly the monomer packing in the homodimer as illustrated by the observed shift to
524 higher charge states in the native MS spectrum (Fig. 5B).

525 Regardless of whether calcium is bound or not, the presence of zinc highly affects mS100A9
526 behavior. The disulfide-crosslinked homodimer becomes predominant, representing 86 % and 80
527 % of the total amount of protein in the presence of zinc alone or zinc and calcium, respectively
528 (Figs. 5C, 5E). The observed molecular mass of this “dimeric” peak increases of +2 Da, suggesting
529 that one of the two SS bridges is lost. Interestingly, native MS shows that the signals of mS100A9
530 monomers are not observed anymore (Figs. 5D, 5F). Moreover, it was quite difficult to record
531 native MS data when zinc was present since the sample tended to aggregate during injection into
532 the mass spectrometer. Thus, as also suggested by our DLS experiments, zinc may promote the
533 formation of high order insoluble oligomers and the recorded spectra may only reflect the soluble
534 fraction of the sample.

535 In the sample with zinc alone, reaction with IAA generates species carrying one acetamide group
536 for the “monomeric” peak (Supplementary Fig. S6A). Pre-treatment with DTT yields species
537 carrying up to 2 acetamide groups (Supplementary Figs. S6B-C). The binding of 3 acetamide
538 groups is not observed, indicating that a maximum of two cysteines per molecule is available. Zinc
539 might hinder solvent accessibility of the third cysteine either because Zn^{2+} -binding sites may
540 directly block the access to this residue or because zinc may promote mS100A9 oligomerization,
541 thereby diminishing solvent exposure of the cysteines buried within the oligomers. Surprisingly,
542 in the presence of both calcium and zinc, no alkylation of the non-covalent species occurs

543 (Supplementary Fig. S7A). Similarly, addition of DTT and IAA leads mainly to the formation of
544 species with 1 acetamide group, and a smaller amount of species with 2 acetamide groups, as well
545 as a certain amount of unreacted protein (Supplementary Figs. S7B-C).

546 Up to four acetamide groups are bound to the disulfide-crosslinked homodimer in the presence of
547 zinc alone (Supplementary Fig. S6D), whereas only two acetamide groups are added in the sole
548 presence of calcium (Supplementary Fig. S5D). This demonstrates loss of one SS bridge upon zinc
549 addition. When calcium and zinc are present, the SS-linked homodimer is almost unreactive
550 towards alkylation, the major form observed is the unreacted protein, whose mass corresponds to
551 a dimer carrying one intersubunit SS bridge (Supplementary Fig. S7D). Small amounts of
552 homodimers with 1 and 2 acetamide groups are also detected but clearly the cysteines are much
553 less accessible to IAA when both cations are present. Taken together, these data suggest that zinc
554 act as a modulator of the disulfide bonding pattern of mS100A9. It promotes the assembly of
555 covalent, SS-crosslinked dimers and affects the accessibility of the other unliganded cysteines.

556 ***3.5. The formation of distinct SS bridges allows switching between the different homodimeric*** 557 ***forms of mS100A9***

558 In order to identify which of the three cysteines of mS100A9 are involved in the intramolecular
559 and inter-subunit disulfide bridges, point mutations into alanine were introduced for each cysteine
560 residue. Only the dimeric fraction of the samples was pooled from the SEC column
561 (Supplementary Fig. S8). These dimeric pools were first analyzed by SDS-PAGE under non-
562 reducing conditions for all four ionic conditions tested. As shown in Figure 6A, regardless of the
563 metal present, almost no disulfide-crosslinked dimer is observed for the C111A mutant, whereas
564 the C91A mutant forms almost exclusively the disulfide-crosslinked dimers. For both the WT
565 protein and the C80A mutant, a mixture of monomers and SS-linked dimers is present. The relative

566 proportion of monomers and dimers is however difficult to evaluate and it is apparently not highly
567 influenced by cations (Figure 6A).

568 In order to assess the mass of the species with high accuracy and sensitivity, the three Cys-to-Ala
569 mutants were analyzed by LC/ESI-TOF-MS. C111A mutant is unable to form the disulfide-
570 crosslinked homodimer, regardless of the cations present (Figure 6B), in agreement with our SDS-
571 PAGE experiments. This indicates that Cys111 is responsible for the formation of inter-subunit
572 SS bridge(s). In all four ionic conditions, the “monomeric” peak has an experimental molecular
573 mass of 13145.2 Da. This mass indicates that the two non-mutated cysteines, Cys80 and Cys91,
574 are in the reduced state, regardless of the presence or absence of metal ions. Consistently, treatment
575 of the protein with IAA leads to the binding of two acetamide groups per subunit, when there is
576 Ca only, Zn only or no metal (Supplementary Fig. S10A). When both zinc and calcium are present,
577 one cysteine is less accessible to react with IAA. These data rule out the formation of an
578 intramolecular bridge between Cys80 and Cys91, and suggest that Cys111 also participates in the
579 intramolecular SS links. Alternatively, Cys111 mutation into alanine may affect the overall
580 architecture of the S100A9 molecule in such a way that the SS bridge between Cys80 and Cys91
581 cannot be formed. As Cys111 is located at the very end of mS100A9 C-terminal tail, in a highly
582 flexible and unstructured region, it seems however unlikely that the C111A mutation may modify
583 significantly the architecture of the protein core.

584 By contrast, the C91A mutant is exclusively present as disulfide-crosslinked dimers, in all ionic
585 conditions screened (Fig. 6C). The measured molecular mass indicates a homodimer containing
586 one inter-subunit SS bond and two reduced cysteines. Consistently, reaction with IAA leads mainly
587 to the addition of 2 acetamide groups, except when both zinc and calcium are present. In that case,
588 the protein is mostly present in its non-alkylated form (Supplementary Fig. S10B). These

589 observations suggest that Cys91 is not essential to the formation of the SS-linked homodimer and
590 that Cys91 mutation frees two cysteines by removing one of the SS bonds present within the
591 disulfide-crosslinked dimer.

592 In the case of the C80A mutant, different forms of mS100A9 are in equilibrium (Fig. 6D). In the
593 absence of metals or in the presence of zinc, the disulfide-crosslinked homodimer represents the
594 most abundant form of the protein whereas non-covalent species are slightly prevailing in the
595 presence of calcium alone. The “monomeric” peak has a molecular mass consistent with one
596 intramolecular SS bridge per mS100A9 subunit (Fig. 6D). Moreover, reaction with IAA does not
597 result in alkylation of the protein, demonstrating that the two non-mutated cysteines, Cys 91 and
598 Cys111, are not available to react due to their engagement in the intramolecular SS link
599 (Supplementary Fig. S10C). The disulfide-crosslinked homodimer displays a mass indicating the
600 presence of a single inter-subunit SS bridge and two reduced cysteines. These residues are
601 available for alkylation by IAA, when there is calcium or zinc or no metals (Supplementary Fig.
602 S10D). When both zinc and calcium are present, the unreacted protein represents the major species.
603 This may be explained by oligomerization and/or local conformational changes hindering access
604 to free cysteines.

605 In a further effort to unravel how the three cysteines interact with each other, in particular within
606 the disulfide-crosslinked homodimer, we aimed to crystallize the three Cys-to-Ala mS100A9 point
607 mutants in the various ionic conditions screened. We managed to obtain crystals for the mS100A9
608 C80A mutant, in the presence of calcium and zinc, in the same crystallization conditions than for
609 the WT protein. These crystals diffracted X-rays to 2.35 Å resolution (Table 1, Supplementary
610 Table S2). The structure of the $\text{Ca}^{2+}/\text{Zn}^{2+}$ -bound point mutant was determined by MR using the
611 structure of the WT protein obtained in this study. The resulting structural model is reported in

612 Figure 7A and the quality of the fit with the electron density map is depicted in Supplementary
613 Figure S11A. The overall structure of the mutant is highly similar to the structure of the WT
614 protein, with an r.m.s.d. value on C α atoms of 0.2 Å between the two structures (Fig. 7A). As for
615 the WT protein, the C80A mutant forms a non-covalent homodimer with two calcium and two zinc
616 bound per protomer and one intramolecular SS bridge connecting Cys91 and Cys111 (Fig. 7A,
617 Supplementary Fig. 11B). This second structure confirms that within the non-covalent species,
618 Cys80 is not involved in the formation of intramolecular SS bonds.

619 In summary, our results indicate that Cys91 and Cys111 are able to form an intramolecular SS
620 bridge in the absence or presence of calcium and/or zinc. Characterization of the SS inter-subunit
621 bridges in the disulfide-crosslinked dimer is more complex. The dimer strongly relies on Cys111,
622 whether metals are present or not. It contains two SS bridges, one of which is lost upon addition
623 of zinc as well as when Cys80 or Cys91 are point-mutated. There may not be a single SS-linked
624 homodimeric form of mS100A9 and the protein may display quite some flexibility in the way its
625 subunits are connected through disulfide bridges.

626 **4. Discussion**

627 In this study, we provided a detailed *in vitro* investigation of the homodimerization and disulfide
628 bond pattern of murine S100A9 and we examined how divalent cations affect these properties. We
629 described the first crystallographic structures of mS100A9 (WT and C80A mutant) obtained in the
630 presence of calcium and zinc. They revealed a canonical architecture for the mS100A9
631 homodimer, with both protomers arranged in a centro-symmetrical fashion, as observed for most
632 other S100 proteins. The structures also suggested that mS100A9 is able to chelate two zinc ions
633 per subunit, in contrast to what has been reported so far for other members of the family. Indeed,
634 besides the canonical His₃Asp Zn-motif, our structural data uncovered a second, His₃Glu

635 tetrahedral Zn^{2+} -binding site formed by the HxHxH motif within mS100A9 C-terminal tail and a
636 glutamate side chain coming from a symmetry-related molecule in the protein crystal. This second
637 type of metal-binding site has not been observed in the structures of Mn^{2+} - or Ni^{2+} -bound human
638 S100A8/A9 (Damo et al., 2013; Gagnon et al., 2015; Nakashige et al., 2017; Nakashige et al.,
639 2018). Moreover, it has been proposed that S100A8/A9 also uses the octahedral His_6 site to chelate
640 zinc (Nakashige et al., 2016).

641 The accurate mechanism and stoichiometry of zinc chelation by the S100A9 homodimer has not
642 been characterized yet. It was reported that a truncated version of mS100A9 encompassing only
643 the first 102 residues (i.e. lacking the three His residues from the C-terminal tail), binds
644 substantially less zinc than the WT protein (Raftery et al., 1999). More recently, Harms and
645 coworkers proposed a biphasic zinc binding mode for the hS100A9 homodimer (unpublished
646 results). In their model, both the His20/Asp30/His91/His95 tetrad and the C-terminal histidines
647 may contribute to zinc chelation, possibly through two distinct binding sites (Loes et al., 2019).
648 These data are consistent with our structural observations of two independent Zn-sites per
649 mS100A9 protomer but they still require confirmation. On the other hand, our ITC experiments
650 (Figs. 3A-B) suggest that in solution, only one zinc ion is bound per mS100A9 subunit, with an
651 affinity much lower than that reported for human calprotectin (Kehl-Fie et al., 2011; Brophy et al.,
652 2012). If the affinity of the second Zn-site is even lower or if the binding is entropy driven, we
653 may not detect it by ITC. In conclusion, we cannot evidence the existence of a second Zn-binding
654 site per mS100A9 protomer in solution, but our structural data still highlight that such a site is
655 geometrically possible. Whether this site is a crystallization artifact or whether it can be formed *in*
656 *vivo* remains to be determined. This Zn-site may not exist in the context of the sole mS100A9
657 homodimer, especially knowing that one of the coordinating residues would be missing. It could

658 for example be pertinent for mS100A9 interaction with specific binding partners, in particular
659 those whose interaction has been described as zinc-dependent (Bjork et al., 2009).

660 The non-covalent mS100A9 homodimers we observe both in our crystal structure and in solution,
661 through MS analysis, all contain an intramolecular bridge in each S100A9 subunit, between Cys91
662 and Cys111. This finding correlates with older reports mentioning an intramolecular SS bridge in
663 the protein (Raftery et al., 1998). It remains however uncertain whether all these non-covalent
664 forms display a canonical S100A9/S100A9 arrangement, as reported in our crystallographic
665 models. Remarkably, the Cys91-Cys111 bond leads the otherwise flexible C-terminal tail to adopt
666 a rigidified architecture by folding back over the tip of helix H4. This mechanism seems to be zinc-
667 independent since the disulfide bond pattern of the non-covalent homodimers is not affected by
668 divalent cations. As a consequence, mS100A9 C-terminal tail adopts a conformation unique to the
669 murine protein, regardless of the ions present. Behaviourial differences between murine and
670 human S100 proteins have been described for several members of the family, including S100A8
671 (Lackmann et al., 1993; Lim et al., 2009). This is also the case for S100A9: hS100A9 is generally
672 considered as pro-inflammatory, especially in a cancer context (Gebhardt et al., 2006), whereas
673 mS100A9 may rather display anti-inflammatory properties (Dale et al., 2006; Otsuka et al., 2009;
674 Gomes et al., 2013; Wang et al., 2018b). These latter properties were attributed to mS100A9 C-
675 terminal tail, which can inhibit hyperalgesia by modulating calcium channel signaling in sensory
676 neurons (Dale et al., 2009). However, the mS100A9 C-terminal peptide used in these studies
677 lacked both cysteines involved in the intramolecular SS-bridge. Consequently, it would not adopt
678 the hairpin-like 3D-fold we observe in our structures. Modulation of the 3D-architecture of
679 S100A9 C-terminal tail should therefore be taken into account when designing peptides with more
680 potent antinociceptive effects. Furthermore, the unique architecture of mS100A9 C-terminal tail

681 should be kept in mind when comparing the physiological properties of hS100A9 and mS100A9.
682 While the interconversion between pro- and anti-inflammatory functions for S100A9 is possibly
683 influenced by both the pathological and the cell contexts, differential properties observed between
684 human and murine S100A9 may also be inherent to their distinct 3D-architectures, especially in
685 their C-terminal region known to be critical for effector binding.

686 Formation of disulfide-crosslinked S100A9 homodimers has already been described in the
687 literature (Shibata et al., 2004). Our MS data provide novel insights into these disulfide-crosslinked
688 species and how divalent cations may influence their formation. Indeed, we observed that the SS-
689 linked homodimers bear one inter-subunit disulfide bridge, which strongly relies on Cys111, and
690 a second SS bond, either inter- or intramolecular, which is lost when zinc is added or when Cys80
691 or Cys91 are mutated. It is not straightforward to reconcile all these observations in a single model.
692 The Cys111-Cys111 interaction is the sole inter-subunit SS bridge consistent with a canonical
693 S100A9 homodimer (Fig. 7B). Other inter-subunit interactions would require a substantial
694 repositioning of the two S100A9 protomers with respect to each other and/or conformational
695 changes within each protomer. Other models for which the S100A9/S100A9 arrangement differs
696 dramatically from the canonical configuration we observe in our crystal structures may also help
697 describe these SS-linked homodimers. For example, some of these forms may adopt a two-fold
698 symmetrical homodimeric arrangement, similar to the one we observed for S100A6 in complex
699 with the full-length RAGE ectodomain (Yatime et al., 2016). Interestingly, we speculated at that
700 time that the novel S100A6 conformation may be utilized by other S100 proteins, possibly
701 stabilized by inter-subunit SS bond (Yatime et al., 2016; Yatime, 2017). The different SS-
702 crosslinked mS100A9 dimers may also display other yet unraveled quaternary architectures. These
703 models for the disulfide-crosslinked mS100A9 homodimer(s) are still speculative without

704 structural data. Nevertheless, our results clearly indicate that mS100A9 adopts multiple
705 homodimeric arrangements that rely on distinct disulfide bond patterns and are modulated by the
706 cations present. Local calcium/zinc concentrations may also influence the respective proportion of
707 these forms, possibly through metal-induced crosslinking/oligomerization.

708 It becomes more and more evident that not only mS100A9, but also other S100 proteins exist *in*
709 *vivo* as multiple forms, this plasticity helping understand how these proteins can achieve so many
710 diverse and sometimes opposite functions. Disulfide-crosslinked homodimers have been reported,
711 both *in vitro* and *in vivo*, for many other S100 proteins, including S100A2 (Yamaguchi et al.,
712 2016), S100A4 (Haase-Kohn et al., 2011), S100A5 (Schafer et al., 2000), S100A6 (Wojda et al.,
713 1994), S100A8 (Harrison et al., 1999), S100B (Winningham-Major et al., 1989), and the
714 S100A8/A9 heterodimer (Stephan et al., 2018; Hoskin et al., 2019). None of these forms has been
715 characterized from a structural point of view yet, due to the difficulty of isolating them *in vitro*.
716 Nevertheless, evidence has accumulated suggesting that oxidation may contribute to the
717 modulation of S100 function *in vivo*. In the case of the S100A8/A9 heterocomplex, both
718 intramolecular and inter-subunit disulfide crosslinks have been identified (Stephan et al., 2018;
719 Hoskin et al., 2019). The resulting SS-crosslinked complexes were shown *in vitro* to be more
720 susceptible to protease degradation. This suggests a way to remove unnecessary S100A8/A9
721 present in the extracellular space and thereby down-tune both the inflammatory and antimicrobial
722 activities of the heterocomplex (Magon et al., 2015; Stephan et al., 2018; Hoskin et al., 2019).

723 An interplay between metal binding and oxidation-dependent regulation has also been reported for
724 several S100 proteins. For example, disulfide crosslinking of S100A4 in the presence of copper
725 was shown to enhance pro-inflammatory responses in the tumor microenvironment, through
726 increased RAGE signaling (Haase-Kohn et al., 2011). Similarly, SS-linked S100B dimers promote

727 neuronal growth and proliferation of glial cells (Winningham-Major et al., 1989). S100B
728 crosslinking is also induced by excess copper and may stimulate a toxic response, through nitric
729 oxide production, in relevant neuropathological conditions (Matsui Lee et al., 2000). Cu²⁺-
730 oxidized forms of S100A1, S100A2, S100A6, S100B and S100P were also described, leading to
731 SS-crosslinked dimers at least for S100A2 (Yamaguchi et al., 2016). These forms were shown to
732 modulate PP5 phosphatase activity, possibly impacting on apoptotic responses to oxidative stress.
733 Copper-mediated oxidation of murine S100A8 also generated SS-crosslinked dimers that lost their
734 chemotactic properties, thereby preventing leukocyte recruitment (Harrison et al., 1999).
735 Conversely, SS bond formation may also regulate S100 metal binding properties. Formation of an
736 intramolecular disulfide bridge within human S100A7 was shown to enhance metal sequestration
737 by the canonical His3Asp Zn-binding site, through allosteric modulation, thereby increasing
738 S100A7 antimicrobial activity (Cunden et al., 2017).

739 These examples demonstrate how subtle modulations of the 3D/4D-architecture of S100 proteins
740 may dramatically affect their biological properties. Interestingly, reports also start emerging on
741 possible crosslinking between molecules of RAGE, the cognate receptor for several members of
742 the S100 family (Wei et al., 2012; Moysa et al., 2019). All these findings underline the importance
743 of further studying S100 disulfide-crosslinked forms, in order to understand what is their function
744 and which factors/mechanisms promote their formation *in vivo*. The in-depth characterization of
745 these various forms and of their physiological functions will clearly be a prerequisite to propose
746 efficient targeting strategies against S100 proteins in a context where their pro-inflammatory
747 properties become deleterious, while preserving their beneficial functions such as their
748 antimicrobial activity, these antagonistic effects being possibly orchestrated by distinct forms of
749 the proteins.

750 **Accession codes**

751 The structure factors and atomic coordinates for the crystal structures of WT and C80A mS100A9
752 in the presence of calcium and zinc have been deposited in the Protein Data Bank as entries 6ZDY
753 and 6ZFE, respectively (<http://www wwpdb.org/>).

754 **CRedit authorship contribution statement**

755 Luca Signor: Methodology, Investigation, Formal analysis, Visualization, Writing – original draft.
756 Theo Paris: Investigation. Caroline Mas: Methodology, Investigation, Formal analysis,
757 Visualization. Adrien Picard: Investigation. Georges Lutfalla: Funding acquisition. Elisabetta
758 Boeri Erba: Methodology, Investigation, Formal analysis, Resources, Visualization, Writing –
759 original draft. Laure Yatime: Conceptualization, Methodology, Investigation, Formal analysis,
760 Supervision, Resources, Funding acquisition, Visualization, Writing – original draft.

761 **Declaration of Competing Interest**

762 The authors declare that they have no known competing financial interests or personal
763 relationships that could have appeared to influence the work reported in this paper.

764 **Acknowledgements**

765 We thank the beamline staffs at ESRF and SLS for technical assistance. We thank Dr. Mickael
766 Blaise for initial data collection for the WT protein and Dr. Vincent Olieric for help with data
767 collection for the C80A mutant. We are grateful to Rémi Freydier and Léa Causse from the AETE-
768 ISO platform in the Hydrosiences laboratory (Montpellier, France) for their help with the ICP-
769 MS measurements. We thank Dr. Cherine Bechara for fruitful discussion. This work used the
770 platforms of the Grenoble Instruct-ERIC center (ISBG; UMS 3518 CNRS-CEA-UGA-EMBL)

771 within the Grenoble Partnership for Structural Biology (PSB), supported by FRISBI (ANR-10-
772 INBS-05-02) and GRAL, financed within the University Grenoble Alpes graduate school (Ecoles
773 Universitaires de Recherche) CBH-EUR-GS (ANR-17-EURE-0003). IBS acknowledges
774 integration into the Interdisciplinary Research Institute of Grenoble (IRIG, CEA). Financial
775 support to access the ISBG platform was provided by Instruct-ERIC (PID 6047). We also would
776 like to acknowledge the French Infrastructure for Integrated Structural Biology (FRISBI) for
777 providing access to ESRF and the Danish Cancer Society for initial financial support.

778 **Appendix A. Supplementary data**

779 Supplementary data to this article can be found online.

780 **References**

781 Adams, P.D., Afonine, P.V., Bunkoczi, G., Chen, V.B., Davis, I.W., Echols, N. et al., 2010.
782 PHENIX: a comprehensive Python-based system for macromolecular structure solution. *Acta*
783 *Cryst. D* 66, 213-221. <https://doi.org/10.1107/S0907444909052925>.

784
785 Baudier, J., Glasser, N., Gerard, D., 1986. Ions Binding to S100 Proteins .1. Calcium-Binding
786 and Zinc-Binding Properties of Bovine Brain S100-Alpha-Alpha, S100a-(Alpha,Beta), and
787 S100b-(Beta-Beta), Protein - Zn-2+ Regulates Ca-2+ Binding on S100b Protein. *J. Biol. Chem.*
788 261, 8192-8203.

789
790 Bjork, P., Bjork, A., Vogl, T., Stenstrom, M., Liberg, D., Olsson, A. et al., 2009. Identification of
791 human S100A9 as a novel target for treatment of autoimmune disease via binding to quinoline-3-
792 carboxamides. *PLoS Biol* 7, e97. <https://doi.org/10.1371/journal.pbio.1000097>.

793
794 Boeri Erba, E., Petosa, C., 2015. The emerging role of native mass spectrometry in
795 characterizing the structure and dynamics of macromolecular complexes. *Protein Sci* 24, 1176-
796 1192. <https://doi.org/10.1002/pro.2661>.

797
798 Boeri Erba, E., Signor, L., Oliva, M.F., Hans, F., Petosa, C., 2018. Characterizing Intact
799 Macromolecular Complexes Using Native Mass Spectrometry. *Methods Mol Biol* 1764, 133-
800 151. https://doi.org/10.1007/978-1-4939-7759-8_9.

801

802 Boeri Erba, E., Signor, L., Petosa, C., 2020. Exploring the structure and dynamics of
803 macromolecular complexes by native mass spectrometry. *J Proteomics* 222, 103799.
804 <https://doi.org/10.1016/j.jprot.2020.103799>.

805

806 Brodersen, D.E., Nyborg, J., Kjeldgaard, M., 1999. Zinc-binding site of an S100 protein
807 revealed. Two crystal structures of Ca²⁺-bound human psoriasin (S100A7) in the Zn²⁺-loaded
808 and Zn²⁺-free states. *Biochemistry* 38, 1695-1704. <https://doi.org/10.1021/bi982483d>.

809

810 Brophy, M.B., Hayden, J.A., Nolan, E.M., 2012. Calcium ion gradients modulate the zinc
811 affinity and antibacterial activity of human calprotectin. *J. Am. Chem. Soc.* 134, 18089-18100.
812 <https://doi.org/10.1021/ja307974e>.

813

814 Chaabouni, T., Manceau, H., Peoc'h, K., 2016. Interest of fecal calprotectine dosage in
815 inflammatory bowel diseases, state of the art and perspectives. *Ann Biol Clin (Paris)* 74, 385-
816 394. <https://doi.org/10.1684/abc.2016.1172>.

817

818 Chang, C.C., Khan, I., Tsai, K.L., Li, H., Yang, L.W., Chou, R.H. et al., 2016. Blocking the
819 interaction between S100A9 and RAGE V domain using CHAPS molecule: A novel route to
820 drug development against cell proliferation. *Biochim. Biophys. Acta* 1864, 1558-1569.
821 <https://doi.org/10.1016/j.bbapap.2016.08.008>.

822

823 Corbin, B.D., Seeley, E.H., Raab, A., Feldmann, J., Miller, M.R., Torres, V.J. et al., 2008. Metal
824 chelation and inhibition of bacterial growth in tissue abscesses. *Science* 319, 962-965.
825 <https://doi.org/10.1126/science.1152449>.

826

827 Cunden, L.S., Brophy, M.B., Rodriguez, G.E., Flaxman, H.A., Nolan, E.M., 2017. Biochemical
828 and Functional Evaluation of the Intramolecular Disulfide Bonds in the Zinc-Chelating
829 Antimicrobial Protein Human S100A7 (Psoriasin). *Biochemistry* 56, 5726-5738.
830 <https://doi.org/10.1021/acs.biochem.7b00781>.

831

832 Dale, C.S., Altier, C., Cenac, N., Giorgi, R., Juliano, M.A., Juliano, L. et al., 2009. Analgesic
833 properties of S100A9 C-terminal domain: a mechanism dependent on calcium channel inhibition.
834 *Fundam Clin Pharmacol* 23, 427-438. <https://doi.org/10.1111/j.1472-8206.2009.00686.x>.

835

836 Dale, C.S., Pagano Rde, L., Paccola, C.C., Pinotti-Guirao, T., Juliano, M.A., Juliano, L. et al.,
837 2006. Effect of the C-terminus of murine S100A9 protein on experimental nociception. *Peptides*
838 27, 2794-2802. <https://doi.org/10.1016/j.peptides.2006.07.002>.

839

840 Damo, S.M., Kehl-Fie, T.E., Sugitani, N., Holt, M.E., Rathi, S., Murphy, W.J. et al., 2013.
841 Molecular basis for manganese sequestration by calprotectin and roles in the innate immune

842 response to invading bacterial pathogens. *Proc. Natl. Acad. Sci. U. S. A.* 110, 3841-3846.
843 <https://doi.org/10.1073/pnas.1220341110>.

844
845 Davis, I.W., Leaver-Fay, A., Chen, V.B., Block, J.N., Kapral, G.J., Wang, X. et al., 2007.
846 MolProbity: all-atom contacts and structure validation for proteins and nucleic acids. *Nucleic*
847 *Acids Res.* 35, W375-383. <https://doi.org/10.1093/nar/gkm216>.

848
849 Donato, R., Cannon, B.R., Sorci, G., Riuzzi, F., Hsu, K., Weber, D.J. et al., 2013. Functions of
850 S100 proteins. *Curr. Mol. Med.* 13, 24-57.

851
852 Emsley, P., Cowtan, K., 2004. Coot: model-building tools for molecular graphics. *Acta Cryst. D*
853 60, 2126-2132. <https://doi.org/10.1107/S0907444904019158>.

854
855 Gagnon, D.M., Brophy, M.B., Bowman, S.E.J., Stich, T.A., Drennan, C.L., Britt, R.D. et al.,
856 2015. Manganese Binding Properties of Human Calprotectin under Conditions of High and Low
857 Calcium: X-ray Crystallographic and Advanced Electron Paramagnetic Resonance Spectroscopic
858 Analysis. *J. Am. Chem. Soc.* 137, 3004-3016. <https://doi.org/10.1021/ja512204s>.

859
860 Gebhardt, C., Nemeth, J., Angel, P., Hess, J., 2006. S100A8 and S100A9 in inflammation and
861 cancer. *Biochem Pharmacol* 72, 1622-1631. <https://doi.org/10.1016/j.bcp.2006.05.017>.

862
863 Gilston, B.A., Skaar, E.P., Chazin, W.J., 2016. Binding of transition metals to S100 proteins. *Sci*
864 *China Life Sci* 59, 792-801. <https://doi.org/10.1007/s11427-016-5088-4>.

865
866 Giudice, V., Wu, Z., Kajigaya, S., Fernandez Ibanez, M.D.P., Rios, O., Cheung, F. et al., 2019.
867 Circulating S100A8 and S100A9 protein levels in plasma of patients with acquired aplastic
868 anemia and myelodysplastic syndromes. *Cytokine* 113, 462-465.
869 <https://doi.org/10.1016/j.cyto.2018.06.025>.

870
871 Glaser, R., Harder, J., Lange, H., Bartels, J., Christophers, E., Schroder, J.M., 2005.
872 Antimicrobial psoriasin (S100A7) protects human skin from *Escherichia coli* infection. *Nat*
873 *Immunol* 6, 57-64. <https://doi.org/10.1038/ni1142>.

874
875 Goebeler, M., Roth, J., van den Bos, C., Ader, G., Sorg, C., 1995. Increase of calcium levels in
876 epithelial cells induces translocation of calcium-binding proteins migration inhibitory factor-
877 related protein 8 (MRP8) and MRP14 to keratin intermediate filaments. *Biochem J* 309 (Pt 2),
878 419-424.

879

880 Gomes, L.H., Raftery, M.J., Yan, W.X., Goyette, J.D., Thomas, P.S., Geczy, C.L., 2013. S100A8
881 and S100A9-oxidant scavengers in inflammation. *Free Radic Biol Med* 58, 170-186.
882 <https://doi.org/10.1016/j.freeradbiomed.2012.12.012>.

883

884 Gonzalez, L.L., Garrie, K., Turner, M.D., 2020. Role of S100 proteins in health and disease.
885 *Biochim. Biophys. Acta Mol. Cell Res.* 1867, 118677.
886 <https://doi.org/10.1016/j.bbamcr.2020.118677>.

887

888 Haase-Kohn, C., Wolf, S., Lenk, J., Pietzsch, J., 2011. Copper-mediated cross-linking of
889 S100A4, but not of S100A2, results in proinflammatory effects in melanoma cells. *Biochem.*
890 *Biophys. Res. Commun.* 413, 494-498. <https://doi.org/10.1016/j.bbrc.2011.08.132>.

891

892 Harrison, C.A., Raftery, M.J., Walsh, J., Alewood, P., Iismaa, S.E., Thliveris, S. et al., 1999.
893 Oxidation regulates the inflammatory properties of the murine S100 protein S100A8. *J. Biol.*
894 *Chem.* 274, 8561-8569.

895

896 Hoskin, T.S., Crowther, J.M., Cheung, J., Epton, M.J., Sly, P.D., Elder, P.A. et al., 2019.
897 Oxidative cross-linking of calprotectin occurs in vivo, altering its structure and susceptibility to
898 proteolysis. *Redox Biology* 24<https://doi.org/Artn 101202>
899 [10.1016/J.Redox.2019.101202](https://doi.org/10.1016/J.Redox.2019.101202).

900

901 Hunter, M.J., Chazin, W.J., 1998. High level expression and dimer characterization of the S100
902 EF-hand proteins, migration inhibitory factor-related proteins 8 and 14. *J. Biol. Chem.* 273,
903 12427-12435. <https://doi.org/10.1074/jbc.273.20.12427>.

904

905 Ishikawa, K., Nakagawa, A., Tanaka, I., Suzuki, M., Nishihira, J., 2000. The structure of human
906 MRP8, a member of the S100 calcium-binding protein family, by MAD phasing at 1.9 Å
907 resolution. *Acta Cryst. D* 56, 559-566.

908

909 Itou, H., Yao, M., Fujita, I., Watanabe, N., Suzuki, M., Nishihira, J. et al., 2002. The crystal
910 structure of human MRP14 (S100A9), a Ca²⁺-dependent regulator protein in inflammatory
911 process. *J. Mol. Biol.* 316, 265-276. <https://doi.org/10.1006/jmbi.2001.5340>.

912

913 Kabsch, W., 2010. Xds. *Acta Cryst. D* 66, 125-132.
914 <https://doi.org/10.1107/S0907444909047337>.

915

916 Kallberg, E., Tahvili, S., Ivars, F., Leanderson, T., 2018. Induction of S100A9 homodimer
917 formation in vivo. *Biochem. Biophys. Res. Commun.* 500, 564-568.
918 <https://doi.org/10.1016/j.bbrc.2018.04.086>.

919
920 Kehl-Fie, T.E., Chitayat, S., Hood, M.I., Damo, S., Restrepo, N., Garcia, C. et al., 2011. Nutrient
921 Metal Sequestration by Calprotectin Inhibits Bacterial Superoxide Defense, Enhancing
922 Neutrophil Killing of Staphylococcus aureus. *Cell Host Microbe* 10, 158-164.
923 <https://doi.org/10.1016/j.chom.2011.07.004>.

924
925 Kerkhoff, C., Nacken, W., Benedyk, M., Dagher, M.C., Sopalla, C., Doussiere, J., 2005. The
926 arachidonic acid-binding protein S100A8/A9 promotes NADPH oxidase activation by
927 interaction with p67phox and Rac-2. *FASEB J.* 19, 467-469. [https://doi.org/10.1096/fj.04-](https://doi.org/10.1096/fj.04-2377fje)
928 [2377fje](https://doi.org/10.1096/fj.04-2377fje).

929
930 Korndorfer, I.P., Brueckner, F., Skerra, A., 2007. The crystal structure of the human
931 (S100A8/S100A9)₂ heterotetramer, calprotectin, illustrates how conformational changes of
932 interacting alpha-helices can determine specific association of two EF-hand proteins. *J. Mol.*
933 *Biol.* 370, 887-898. <https://doi.org/10.1016/j.jmb.2007.04.065>.

934
935 Kraemer, A.M., Saraiva, L.R., Korsching, S.I., 2008. Structural and functional diversification in
936 the teleost S100 family of calcium-binding proteins. *BMC Evol Biol* 8, 48.
937 <https://doi.org/10.1186/1471-2148-8-48>.

938
939 Lackmann, M., Rajasekariah, P., Iismaa, S.E., Jones, G., Cornish, C.J., Hu, S. et al., 1993.
940 Identification of a chemotactic domain of the pro-inflammatory S100 protein CP-10. *J Immunol*
941 150, 2981-2991.

942
943 Lagasse, E., Weissman, I.L., 1992. Mouse MRP8 and MRP14, two intracellular calcium-binding
944 proteins associated with the development of the myeloid lineage. *Blood* 79, 1907-1915.

945
946 Leclerc, E., Heizmann, C.W., 2011. The importance of Ca²⁺/Zn²⁺ signaling S100 proteins and
947 RAGE in translational medicine. *Front Biosci (Schol Ed)* 3, 1232-1262.
948 <https://doi.org/10.2741/223>.

949
950 Leukert, N., Vogl, T., Strupat, K., Reichelt, R., Sorg, C., Roth, J., 2006. Calcium-dependent
951 tetramer formation of S100A8 and S100A9 is essential for biological activity. *J. Mol. Biol.* 359,
952 961-972. <https://doi.org/10.1016/j.jmb.2006.04.009>.

953
954 Lim, S.Y., Raftery, M.J., Geczy, C.L., 2011. Oxidative modifications of DAMPs suppress
955 inflammation: the case for S100A8 and S100A9. *Antioxid Redox Signal* 15, 2235-2248.
956 <https://doi.org/10.1089/ars.2010.3641>.

957

958 Lim, S.Y., Raftery, M.J., Goyette, J., Hsu, K., Geczy, C.L., 2009. Oxidative modifications of
959 S100 proteins: functional regulation by redox. *J. Leukoc. Biol.* 86, 577-587.
960 <https://doi.org/10.1189/jlb.1008608>.

961

962 Lin, H., Andersen, G.R., Yatime, L., 2016. Crystal structure of human S100A8 in complex with
963 zinc and calcium. *BMC Struct. Biol.* 16, 8. <https://doi.org/10.1186/s12900-016-0058-4>.

964

965 Loes, A.N., Shi, R., Harms, M.J., 2019. Zinc-independent activation of Toll-like receptor 4 by
966 S100A9. *bioRxiv*, 796219. <https://doi.org/10.1101/796219>.

967

968 Longbottom, D., Sallenave, J.M., van Heyningen, V., 1992. Subunit structure of calgranulins A
969 and B obtained from sputum, plasma, granulocytes and cultured epithelial cells. *Biochim.*
970 *Biophys. Acta* 1120, 215-222. [https://doi.org/10.1016/0167-4838\(92\)90273-g](https://doi.org/10.1016/0167-4838(92)90273-g).

971

972 Ma, L., Sun, P., Zhang, J.C., Zhang, Q., Yao, S.L., 2017. Proinflammatory effects of S100A8/A9
973 via TLR4 and RAGE signaling pathways in BV-2 microglial cells. *Int J Mol Med* 40, 31-38.
974 <https://doi.org/10.3892/ijmm.2017.2987>.

975

976 Madeira, F., Park, Y.M., Lee, J., Buso, N., Gur, T., Madhusoodanan, N. et al., 2019. The EMBL-
977 EBI search and sequence analysis tools APIs in 2019. *Nucleic Acids Res.* 47, W636-W641.
978 <https://doi.org/10.1093/nar/gkz268>.

979

980 Magon, N.J., Turner, R., Gearry, R.B., Hampton, M.B., Sly, P.D., Kettle, A.J., 2015. Oxidation
981 of calprotectin by hypochlorous acid prevents chelation of essential metal ions and allows
982 bacterial growth: Relevance to infections in cystic fibrosis. *Free Radic Biol Med* 86, 133-144.
983 <https://doi.org/10.1016/j.freeradbiomed.2015.05.022>.

984

985 Marenholz, I., Heizmann, C.W., Fritz, G., 2004. S100 proteins in mouse and man: from
986 evolution to function and pathology (including an update of the nomenclature). *Biochem.*
987 *Biophys. Res. Commun.* 322, 1111-1122. <https://doi.org/10.1016/j.bbrc.2004.07.096>.

988

989 Marinkovic, G., Grauen Larsen, H., Yndigegn, T., Szabo, I.A., Mares, R.G., de Camp, L. et al.,
990 2019. Inhibition of pro-inflammatory myeloid cell responses by short-term S100A9 blockade
991 improves cardiac function after myocardial infarction. *Eur Heart J* 40, 2713-2723.
992 <https://doi.org/10.1093/eurheartj/ehz461>.

993

994 Matsui Lee, I.S., Suzuki, M., Hayashi, N., Hu, J., Van Eldik, L.J., Titani, K. et al., 2000. Copper-
995 dependent formation of disulfide-linked dimer of S100B protein. *Arch Biochem Biophys* 374,
996 137-141. <https://doi.org/10.1006/abbi.1999.1595>.

997

998 McCoy, A.J., Grosse-Kunstleve, R.W., Adams, P.D., Winn, M.D., Storoni, L.C., Read, R.J.,
999 2007. Phaser crystallographic software. *J. Appl. Crystallogr.* 40, 658-674.
1000 <https://doi.org/10.1107/S0021889807021206>.

1001
1002 Morgner, N., Robinson, C.V., 2012. Massign: an assignment strategy for maximizing
1003 information from the mass spectra of heterogeneous protein assemblies. *Anal Chem* 84, 2939-
1004 2948. <https://doi.org/10.1021/ac300056a>.

1005
1006 Moroz, O.V., Antson, A.A., Grist, S.J., Maitland, N.J., Dodson, G.G., Wilson, K.S. et al., 2003.
1007 Structure of the human S100A12-copper complex: implications for host-parasite defence. *Acta*
1008 *Cryst. D* 59, 859-867. <https://doi.org/10.1107/s0907444903004700>.

1009
1010 Moroz, O.V., Antson, A.A., Murshudov, G.N., Maitland, N.J., Dodson, G.G., Wilson, K.S. et al.,
1011 2001. The three-dimensional structure of human S100A12. *Acta Cryst. D* 57, 20-29.
1012 <https://doi.org/10.1107/s090744490001458x>.

1013
1014 Moroz, O.V., Blagova, E.V., Wilkinson, A.J., Wilson, K.S., Bronstein, I.B., 2009a. The crystal
1015 structures of human S100A12 in apo form and in complex with zinc: new insights into S100A12
1016 oligomerisation. *J. Mol. Biol.* 391, 536-551. <https://doi.org/10.1016/j.jmb.2009.06.004>.

1017
1018 Moroz, O.V., Burkitt, W., Wittkowski, H., He, W., Ianoul, A., Novitskaya, V. et al., 2009b. Both
1019 Ca²⁺ and Zn²⁺ are essential for S100A12 protein oligomerization and function. *BMC Biochem.*
1020 10, 11. <https://doi.org/10.1186/1471-2091-10-11>.

1021
1022 Moroz, O.V., Wilson, K.S., Bronstein, I.B., 2011. The role of zinc in the S100 proteins: insights
1023 from the X-ray structures. *Amino Acids* 41, 761-772. [https://doi.org/10.1007/s00726-010-0540-](https://doi.org/10.1007/s00726-010-0540-4)
1024 4.

1025
1026 Moysa, A., Hammerschmid, D., Szczepanowski, R.H., Sobott, F., Dadlez, M., 2019. Enhanced
1027 oligomerization of full-length RAGE by synergy of the interaction of its domains. *Sci Rep* 9,
1028 20332. <https://doi.org/10.1038/s41598-019-56993-9>.

1029
1030 Murray, J.I., Tonkin, M.L., Whiting, A.L., Peng, F., Farnell, B., Cullen, J.T. et al., 2012.
1031 Structural characterization of S100A15 reveals a novel zinc coordination site among S100
1032 proteins and altered surface chemistry with functional implications for receptor binding. *BMC*
1033 *Struct. Biol.* 12, 16. <https://doi.org/10.1186/1472-6807-12-16>.

1034
1035 Nacken, W., Sopalla, C., Propper, C., Sorg, C., Kerkhoff, C., 2000. Biochemical characterization
1036 of the murine S100A9 (MRP14) protein suggests that it is functionally equivalent to its human

1037 counterpart despite its low degree of sequence homology. *European Journal of Biochemistry*
1038 267, 560-565. <https://doi.org/DOI 10.1046/j.1432-1327.2000.01040.x>.

1039
1040 Nakashige, T.G., Bowman, S.E.J., Zygiel, E.M., Drennan, C.L., Nolan, E.M., 2018. Biophysical
1041 Examination of the Calcium-Modulated Nickel-Binding Properties of Human Calprotectin
1042 Reveals Conformational Change in the EF-Hand Domains and His3Asp Site. *Biochemistry* 57,
1043 4155-4164. <https://doi.org/10.1021/acs.biochem.8b00415>.

1044
1045 Nakashige, T.G., Stephan, J.R., Cunden, L.S., Brophy, M.B., Wommack, A.J., Keegan, B.C. et
1046 al., 2016. The Hexahistidine Motif of Host-Defense Protein Human Calprotectin Contributes to
1047 Zinc Withholding and Its Functional Versatility. *J. Am. Chem. Soc.* 138, 12243-12251.
1048 <https://doi.org/10.1021/jacs.6b06845>.

1049
1050 Nakashige, T.G., Zhang, B., Krebs, C., Nolan, E.M., 2015. Human calprotectin is an iron-
1051 sequestering host-defense protein. *Nat. Chem. Biol.* 11, 765-771.
1052 <https://doi.org/10.1038/nchembio.1891>.

1053
1054 Nakashige, T.G., Zygiel, E.M., Drennan, C.L., Nolan, E.M., 2017. Nickel Sequestration by the
1055 Host-Defense Protein Human Calprotectin. *J. Am. Chem. Soc.* 139, 8828-8836.
1056 <https://doi.org/10.1021/jacs.7b01212>.

1057
1058 Nakatani, Y., Yamazaki, M., Chazin, W.J., Yui, S., 2005. Regulation of S100A8/A9
1059 (calprotectin) binding to tumor cells by zinc ion and its implication for apoptosis-inducing
1060 activity. *Mediators Inflamm* 2005, 280-292. <https://doi.org/10.1155/MI.2005.280>.

1061
1062 Ostendorp, T., Diez, J., Heizmann, C.W., Fritz, G., 2011. The crystal structures of human S100B
1063 in the zinc- and calcium-loaded state at three pH values reveal zinc ligand swapping. *Biochim.*
1064 *Biophys. Acta* 1813, 1083-1091. <https://doi.org/10.1016/j.bbamcr.2010.10.006>.

1065
1066 Ostendorp, T., Leclerc, E., Galichet, A., Koch, M., Demling, N., Weigle, B. et al., 2007.
1067 Structural and functional insights into RAGE activation by multimeric S100B. *EMBO J* 26,
1068 3868-3878. <https://doi.org/10.1038/sj.emboj.7601805>.

1069
1070 Otsuka, K., Terasaki, F., Ikemoto, M., Fujita, S., Tsukada, B., Katashima, T. et al., 2009.
1071 Suppression of inflammation in rat autoimmune myocarditis by S100A8/A9 through modulation
1072 of the proinflammatory cytokine network. *Eur J Heart Fail* 11, 229-237.
1073 <https://doi.org/10.1093/eurjhf/hfn049>.

1074

1075 Paccola, C.C., Gutierrez, V.P., Longo, I., Juliano, L., Juliano, M.A., Giorgi, R., 2008.
1076 Antinociceptive effect of the C-terminus of murine S100A9 protein on experimental neuropathic
1077 pain. *Peptides* 29, 1806-1814. <https://doi.org/10.1016/j.peptides.2008.05.023>.

1078
1079 Pagano, R.L., Moraes, N.F., De Lorenzo, B.H., Coccuzzo Sampaio, S., Mariano, M., Giorgi, R.,
1080 2014. Inhibition of macrophage functions by the C-terminus of murine S100A9 is dependent on
1081 B-1 cells. *Mediators Inflamm* 2014, 836491. <https://doi.org/10.1155/2014/836491>.

1082
1083 Pruenster, M., Vogl, T., Roth, J., Sperandio, M., 2016. S100A8/A9: From basic science to
1084 clinical application. *Pharmacol Ther* 167, 120-131.
1085 <https://doi.org/10.1016/j.pharmthera.2016.07.015>.

1086
1087 Raftery, M.J., Collinson, L., Geczy, C.L., 1999. Overexpression, oxidative refolding, and zinc
1088 binding of recombinant forms of the murine S100 protein MRP14 (S100A9). *Protein Expr Purif*
1089 15, 228-235. <https://doi.org/10.1006/prev.1998.1015>.

1090
1091 Raftery, M.J., Geczy, C.L., 1998. Identification of posttranslational modifications and cDNA
1092 sequencing errors in the rat S100 proteins MRP8 and 14 using electrospray ionization mass
1093 spectrometry. *Anal Biochem* 258, 285-292. <https://doi.org/10.1006/abio.1997.2601>.

1094
1095 Raftery, M.J., Harrison, C.A., Alewood, P., Jones, A., Geczy, C.L., 1996. Isolation of the murine
1096 S100 protein MRP14 (14 kDa migration-inhibitory-factor-related protein) from activated spleen
1097 cells: characterization of post-translational modifications and zinc binding. *Biochem J* 316 (Pt
1098 1), 285-293. <https://doi.org/10.1042/bj3160285>.

1099
1100 Realegeno, S., Kelly-Scumpia, K.M., Dang, A.T., Lu, J., Teles, R., Liu, P.T. et al., 2016.
1101 S100A12 Is Part of the Antimicrobial Network against *Mycobacterium leprae* in Human
1102 Macrophages. *PLoS Pathog.* 12, e1005705. <https://doi.org/10.1371/journal.ppat.1005705>.

1103
1104 Reeb, A.N., Li, W., Sewell, W., Marlow, L.A., Tun, H.W., Smallridge, R.C. et al., 2015. S100A8
1105 is a novel therapeutic target for anaplastic thyroid carcinoma. *J Clin Endocrinol Metab* 100,
1106 E232-242. <https://doi.org/10.1210/jc.2014-2988>.

1107
1108 Roh, J.S., Sohn, D.H., 2018. Damage-Associated Molecular Patterns in Inflammatory Diseases.
1109 *Immune netw.* 18, e27. <https://doi.org/10.4110/in.2018.18.e27>.

1110
1111 Sakaguchi, M., Yamamoto, M., Miyai, M., Maeda, T., Hiruma, J., Murata, H. et al., 2016.
1112 Identification of an S100A8 Receptor Neuroplastin-beta and its Heterodimer Formation with
1113 EMMPRIN. *J Invest Dermatol* 136, 2240-2250. <https://doi.org/10.1016/j.jid.2016.06.617>.

1114

1115 Schafer, B.W., Fritschy, J.M., Murmann, P., Troxler, H., Durussel, I., Heizmann, C.W. et al.,
1116 2000. Brain S100A5 is a novel calcium-, zinc-, and copper ion-binding protein of the EF-hand
1117 superfamily. *Journal of Biological Chemistry* 275, 30623-30630. <https://doi.org/DOI>
1118 10.1074/jbc.M002260200.

1119
1120 Shabani, F., Farasat, A., Mahdavi, M., Gheibi, N., 2018. Calprotectin (S100A8/S100A9): a key
1121 protein between inflammation and cancer. *Inflamm Res* 67, 801-812.
1122 <https://doi.org/10.1007/s00011-018-1173-4>.

1123
1124 Shibata, F., Miyama, K., Shinoda, F., Mizumoto, J., Takano, K., Nakagawa, H., 2004. Fibroblast
1125 growth-stimulating activity of S100A9 (MRP-14). *Eur J Biochem* 271, 2137-2143.
1126 <https://doi.org/10.1111/j.1432-1033.2004.04129.x>.

1127
1128 Sievers, F., Higgins, D.G., 2018. Clustal Omega for making accurate alignments of many protein
1129 sequences. *Protein Sci* 27, 135-145. <https://doi.org/10.1002/pro.3290>.

1130
1131 Sobott, F., Hernandez, H., McCammon, M.G., Tito, M.A., Robinson, C.V., 2002. A tandem mass
1132 spectrometer for improved transmission and analysis of large macromolecular assemblies. *Anal*
1133 *Chem* 74, 1402-1407. <https://doi.org/10.1021/ac0110552>.

1134
1135 Stephan, J.R., Yu, F.T., Costello, R.M., Bleier, B.S., Nolan, E.M., 2018. Oxidative Post-
1136 translational Modifications Accelerate Proteolytic Degradation of Calprotectin. *J. Am. Chem.*
1137 *Soc.* 140, 17444-17455. <https://doi.org/10.1021/jacs.8b06354>.

1138
1139 Striz, I., Trebichavsky, I., 2004. Calprotectin - a pleiotropic molecule in acute and chronic
1140 inflammation. *Physiol Res* 53, 245-253.

1141
1142 Tomonobu, N., Kinoshita, R., Sakaguchi, M., 2020. S100 Soil Sensor Receptors and Molecular
1143 Targeting Therapy Against Them in Cancer Metastasis. *Transl Oncol* 13, 100753.
1144 <https://doi.org/10.1016/j.tranon.2020.100753>.

1145
1146 Unno, M., Kawasaki, T., Takahara, H., Heizmann, C.W., Kizawa, K., 2011. Refined crystal
1147 structures of human Ca(2+)/Zn(2+)-binding S100A3 protein characterized by two disulfide
1148 bridges. *J. Mol. Biol.* 408, 477-490. <https://doi.org/10.1016/j.jmb.2011.02.055>.

1149
1150 van den Heuvel, R.H., van Duijn, E., Mazon, H., Synowsky, S.A., Lorenzen, K., Versluis, C. et
1151 al., 2006. Improving the performance of a quadrupole time-of-flight instrument for
1152 macromolecular mass spectrometry. *Anal Chem* 78, 7473-7483.
1153 <https://doi.org/10.1021/ac061039a>.

1154

1155 Vogl, T., Leukert, N., Barczyk, K., Strupat, K., Roth, J., 2006. Biophysical characterization of
1156 S100A8 and S100A9 in the absence and presence of bivalent cations. *Biochim. Biophys. Acta*
1157 1763, 1298-1306. <https://doi.org/10.1016/j.bbamcr.2006.08.028>.

1158
1159 Wang, C., Iashchishyn, I.A., Pansieri, J., Nystrom, S., Klementieva, O., Kara, J. et al., 2018a.
1160 S100A9-Driven Amyloid-Neuroinflammatory Cascade in Traumatic Brain Injury as a Precursor
1161 State for Alzheimer's Disease. *Sci Rep* 8, 12836. <https://doi.org/10.1038/s41598-018-31141-x>.

1162
1163 Wang, Q., Chen, W., Lin, J., 2019. The Role of Calprotectin in Rheumatoid Arthritis. *J Transl*
1164 *Int Med* 7, 126-131. <https://doi.org/10.2478/jtim-2019-0026>.

1165
1166 Wang, S., Song, R., Wang, Z., Jing, Z., Wang, S., Ma, J., 2018b. S100A8/A9 in Inflammation.
1167 *Front Immunol* 9, 1298. <https://doi.org/10.3389/fimmu.2018.01298>.

1168
1169 Wei, W., Lampe, L., Park, S., Vangara, B.S., Waldo, G.S., Cabantous, S. et al., 2012. Disulfide
1170 bonds within the C2 domain of RAGE play key roles in its dimerization and biogenesis. *PLoS*
1171 *One* 7, e50736. <https://doi.org/10.1371/journal.pone.0050736>.

1172
1173 Winningham-Major, F., Staecker, J.L., Barger, S.W., Coats, S., Van Eldik, L.J., 1989. Neurite
1174 extension and neuronal survival activities of recombinant S100 beta proteins that differ in the
1175 content and position of cysteine residues. *J Cell Biol* 109, 3063-3071.
1176 <https://doi.org/10.1083/jcb.109.6.3063>.

1177
1178 Wojda, U., Kuznicki, J., 1994. Calyculin from Mouse Ehrlich Ascites Tumor-Cells and Rabbit
1179 Lung Form Noncovalent Dimers. *Biochimica Et Biophysica Acta-Protein Structure and*
1180 *Molecular Enzymology* 1209, 248-252. [https://doi.org/Doi 10.1016/0167-4838\(94\)90192-9](https://doi.org/Doi 10.1016/0167-4838(94)90192-9).

1181
1182 Yamaguchi, F., Tsuchiya, M., Shimamoto, S., Fujimoto, T., Tokumitsu, H., Tokuda, M. et al.,
1183 2016. Oxidative Stress Impairs the Stimulatory Effect of S100 Proteins on Protein Phosphatase 5
1184 Activity. *Tohoku Journal of Experimental Medicine* 240, 67-78.
1185 <https://doi.org/10.1620/tjem.240.67>.

1186
1187 Yatime, L., 2017. [A cystein-dependent activation mechanism for the pro-inflammatory ligands
1188 of RAGE?]. *Med Sci (Paris)* 33, 351-354. <https://doi.org/10.1051/medsci/20173303026>.

1189
1190 Yatime, L., 2019. Structural Analysis of S100A8 Complex with Zinc and Calcium: A General
1191 Protocol for the Study of S100 Proteins in the Presence of Divalent Cations by X-Ray
1192 Crystallography. *Methods Mol Biol* 1929, 417-435. https://doi.org/10.1007/978-1-4939-9030-6_26.
1193

1194

1195 Yatime, L., Betzer, C., Jensen, R.K., Mortensen, S., Jensen, P.H., Andersen, G.R., 2016. The
1196 Structure of the RAGE:S100A6 Complex Reveals a Unique Mode of Homodimerization for
1197 S100 Proteins. *Structure* 24, 2043-2052. <https://doi.org/10.1016/j.str.2016.09.011>.

1198
1199 Zackular, J.P., Chazin, W.J., Skaar, E.P., 2015. Nutritional Immunity: S100 Proteins at the Host-
1200 Pathogen Interface. *J. Biol. Chem.* 290, 18991-18998. <https://doi.org/10.1074/jbc.R115.645085>.

1201

1202

1203

1204 **Figure legends**

1205 **Figure 1.** Structure of murine S100A9 in the presence of calcium and zinc. **(A)** General overview
1206 of the structure of the $\text{Ca}^{2+}/\text{Zn}^{2+}$ -bound murine S100A9 (mS100A9) homodimer at 1.45 Å
1207 resolution. The two mS100A9 subunits are shown in beige and purple. Calcium and zinc ions are
1208 displayed as green and yellow spheres, respectively. **(B)** Final electron density map contoured at
1209 1σ and final model superimposed to assess the quality of the fit. **(C)** Anomalous difference Fourier
1210 maps calculated using phases and weight from the best refined atomic model obtained with the
1211 native dataset and anomalous differences from the datasets collected at wavelengths of 1.27 Å
1212 (blue mesh, contour at 5σ) and 1.30 Å (red mesh, contour at 5σ). The final model displayed as
1213 cartoon is superimposed for comparison. **(D)** Superimposition of the mS100A9 protomer from the
1214 X-ray structure of $\text{Ca}^{2+}/\text{Zn}^{2+}$ -bound mS100A9 homodimer (beige, this study) with the hS100A9
1215 moiety from the NMR structure of apo-hS100A9 homodimer (red, PDB_ID 5I8N (Chang et al.,
1216 2016)), from the X-ray structure of Ca^{2+} -bound hS100A9 homodimer (cyan, PDB_ID 1IRJ (Itou
1217 et al., 2002)) and from the X-ray structure of $\text{Ca}^{2+}/\text{Mn}^{2+}$ -bound calprotectin heterocomplex (grey,
1218 PDB_ID 4GGF (Damo et al., 2013)). Superimposition was performed on C-alpha atoms
1219 (mS100A9 residues Glu10 to Leu83). **(E)** Superimposition of the $\text{Ca}^{2+}/\text{Zn}^{2+}$ -bound mS100A9
1220 homodimer (beige, this study) with apo (red, PDB_ID 5I8N (Chang et al., 2016)) and Ca^{2+} -bound

1221 hS100A9 homodimer (cyan, PDB_ID 1IRJ (Itou et al., 2002)). All 3 homodimers are
1222 superimposed on subunit A (superimposition on C-alpha atoms, mS100A9 residues Glu10 to
1223 Leu83). (F) Superimposition of the Ca²⁺/Zn²⁺-bound mS100A9 homodimer (beige, this study)
1224 with Ca²⁺-bound (grey, PDB_ID 1MR8 (Chang et al., 2016)) and Ca²⁺/Zn²⁺-bound hS100A8
1225 homodimer (purple, PDB_ID 5HLO (Itou et al., 2002)). All 3 homodimers are superimposed on
1226 subunit A (superimposition on C-alpha atoms, mS100A9 residues Glu10 to Leu83).

1227 **Figure 2.** The two Zn-binding modes of mS100A9: comparison with hS100A9 and influence on
1228 the conformation of the C-terminal tail. (A) Zoom on the first type of Zn²⁺-binding site of
1229 mS100A9, close to the first Ef-hand motif of subunit A. Anomalous difference Fourier maps
1230 calculated using phases and weight from the best refined atomic model (without ions) obtained
1231 with the native dataset and anomalous differences from datasets collected at different wavelengths
1232 are shown as blue mesh ($\lambda = 1.27 \text{ \AA}$, contour at 3.5σ) or red mesh ($\lambda = 1.30 \text{ \AA}$, contour at 3.5σ).
1233 Residues involved in zinc coordination are shown as sticks. (B) Sequence alignment of the C-
1234 terminal region (Helix H4 + C-terminal tail) of murine and human S100A9. The alignment was
1235 performed in Clustal Omega (Sievers et al., 2018; Madeira et al., 2019). The secondary structure
1236 is displayed schematically above the alignment. The residue numbering indicated below the
1237 alignment corresponds to mS100A9 sequence. Identical residues between the two sequences are
1238 underlined in dark green whereas conserved mutations are highlighted in light green. The three
1239 cysteines of mS100A9 are indicated with a red star. Histidine residues involved in zinc
1240 coordination are marked with orange (Zn-binding site 1) or blue (Zn-binding site 2) triangles for
1241 mS100A9 and with orange spheres (Zn-binding site 1) for hS100A9. (C) Same as panel A but with
1242 the close-up view centered on the second type of Zn²⁺-binding site of mS100A9, within the C-
1243 terminal tail of subunit A. (D) Overview of the C-terminal region of mS100A9 encompassing helix

1244 H4 and the C-terminal tail closing around the second Zn²⁺ binding site. A disulfide bridge connects
1245 Cys91 and Cys111 while Cys80 remains free.

1246 **Figure 3.** Biophysical investigation of zinc binding to the mS100A9 homodimer. **(A)** ITC titrations
1247 and binding isotherms fitted with a one-site model for the binding of Zn²⁺ to apo-mS100A9.
1248 Experiments were performed at least in duplicates. The measured K_d value and stoichiometry for
1249 each particular experiment are indicated on the graph. **(B)** Same as panel **A** but with Ca²⁺-bound
1250 mS100A9 homodimer. **(C)** DLS analysis of apo-mS100A9 in the presence of increasing
1251 concentrations of zinc. Below 3 molar equivalents of zinc, mS100A9 remains homodimeric. At 3
1252 or more equivalents, mS100A9 readily aggregates and forms large oligomers. **(D)** Same as panel
1253 **C** but with Ca²⁺-bound mS100A9.

1254 **Figure 4.** Mass spectrometry analysis of WT mS100A9 in the absence of divalent cations. **(A)**
1255 LC/ESI-TOF-MS deconvoluted spectrum of untreated WT mS100A9. The protein displays two
1256 peaks, one at a mass of 13175.1 Da referred to as the “monomeric” peak (M), and one at 26349.5
1257 Da referred to as the “dimeric” peak (D). **(B)** and **(C)** Native MS spectra of WT mS100A9 either
1258 untreated (panel B) or after treatment with DTT (panel C) prior to MS analysis. Interestingly,
1259 mS100A9 carries less charges in the presence of disulfide bridges. Specifically, the highest peaks
1260 of disulfide-bond containing mS100A9 monomeric and dimeric forms are 7+ and 10+, respectively
1261 (panel B). On the contrary, the highest peaks of the DTT-treated mS100A9 monomers and dimers
1262 are 8+ and 11+, respectively (panel C). These differences in charge reflect the higher degree of
1263 compactness of the disulfide cross-linked mS100A9 protein. **(D)**, **(E)** and **(F)** LC/ESI-TOF-MS
1264 deconvoluted spectra of WT mS100A9 incubated with either DTT alone (DTT, panel D),
1265 iodoacetamide alone (IAA, panel E) or DTT + IAA (panel F) prior to MS analysis. **(G)**
1266 Superimposition of the LC/ESI-TOF-MS deconvoluted spectra obtained for WT mS100A9

1267 without any treatment (upper spectrum), incubation with IAA alone (middle spectrum) or with
1268 DTT + IAA (lower spectrum). The spectra are centered on the region corresponding to the
1269 “monomeric” peak. **(H)** Superimposition of the LC/ESI-TOF-MS deconvoluted spectra obtained
1270 for WT mS100A9 without any treatment (upper spectrum) or incubation urea + DTT + IAA (lower
1271 spectrum). The spectra are centered on the region corresponding to the “monomeric” peak. **(I)**
1272 Superimposition of the LC/ESI-TOF-MS deconvoluted spectra obtained for WT mS100A9
1273 without any treatment (upper spectrum) or after incubation with IAA alone (lower spectrum). The
1274 spectra are centered on the region corresponding to the “dimeric” peak. The relative proportions
1275 of the “monomeric” and “dimeric” peaks (peak area expressed in %) are indicated on the
1276 corresponding graphs where appropriate.

1277 **Figure 5.** Mass spectrometry analysis of WT mS100A9 in the presence of divalent cations. **(A)**
1278 and **(B)** LC/ESI-TOF-MS and native MS spectra of untreated WT mS100A9 in the presence of 1
1279 mM CaCl₂. **(C)** and **(D)** LC/ESI-TOF-MS and native MS spectra of untreated WT mS100A9 in
1280 the presence of 1 mM ZnCl₂. **(E)** and **(F)** LC/ESI-TOF-MS and native MS spectra of untreated
1281 WT mS100A9 in the presence of 1 mM CaCl₂ + 1 mM ZnCl₂. The relative proportions of the
1282 “monomeric” and “dimeric” peaks (peak area expressed in %) are indicated on the LC/ESI-TOF-
1283 MS spectra.

1284 **Figure 6.** Mass spectrometry analysis of the Cys-to-Ala mutants of mS100A9 in the absence or in
1285 the presence of divalent cations. **(A)** SDS-PAGE analysis of WT and mutant mS100A9 in the four
1286 different ionic conditions tested in the study. The sample deposited in each lane is indicated above
1287 the gels. **(B)** Superimposition of the LC/ESI-TOF-MS deconvoluted spectra obtained for untreated
1288 C111A mutant in the absence of ions (upper spectrum), in the presence of 1 mM CaCl₂ (upper
1289 middle spectrum), in the presence of 1 mM ZnCl₂ (lower middle spectrum), or in the presence of

1290 1 mM CaCl₂ + 1 mM ZnCl₂ (lower spectrum). (C) Same as panel B but for mutant C91A. (D)
1291 Same as panel B but for mutant C80A.

1292 **Figure 7.** Structure of Ca²⁺/Zn²⁺-bound mS100A9 C80A and possible models for the disulfide-
1293 crosslinked mS100A9 homodimer. (A) General overview of the structure of the Ca²⁺/Zn²⁺-bound
1294 murine S100A9 C80A mutant (mS100A9-C80A) homodimer at 2.35 Å resolution. The two
1295 mS100A9-C80A subunits are shown in beige and purple. Calcium and zinc ions are displayed as
1296 green and yellow spheres, respectively. The zinc coordinating residues are depicted as sticks. The
1297 structure of the WT mS100A9 protein determined in this study has been superimposed for
1298 comparison (dark blue cartoon). (B) Canonical homodimer conformation of mS100A9 as observed
1299 in our crystal structure. In this configuration, only the two Cys111 from each monomer may reach
1300 out to form an intramolecular SS bridge although they are separated by more than 50Å, due in part
1301 to the side chains protruding from both helices H4. Inter-subunit interaction of Cys111 with Cys80
1302 or Cys91 from the other subunit would require partial unfolding of the second S100A9 protomer
1303 (interactions indicated with a question mark).

1304

1305

1306

1307

1308

1309

1310

1311

1312

	mS100A9 (WT) (native)	mS100A9 (WT) (anomalous)	mS100A9 (WT) (anomalous)	mS100A9 (C80A) (native)
Data collection				
Diffraction source	ID23eh1, ESRF	ID23eh1, ESRF	ID23eh1, ESRF	X06DA, SLS
Wavelength (Å)	1.27	1.27	1.30	1.28
Space group	C2	C2	C2	C2
<i>a</i> , <i>b</i> , <i>c</i> (Å)	72.84, 40.62, 53.09	72.84, 40.62, 53.09	72.97, 40.65, 53.17	73.61, 38.80, 53.17
α , β , γ (°)	90, 125, 90	90, 125, 90	90, 124.99, 90	90, 124.75, 90
Mosaicity (°)	0.28	0.28	0.28	0.41
Resolution range (Å)	80 – 1.45 (1.51 – 1.45)	80 – 1.45 (1.51 – 1.45)	80 – 1.5 (1.57 – 1.5)	80 – 2.35 (2.44 – 2.35)
Total No. of reflections	141507 (13504)	143258 (13475)	130241 (14794)	34129 (3573)
No. of unique reflections	22267 (2406)	43051 (4657)	39043 (4809)	5224 (550)
Completeness (%)	97.6 (92.8)	96.9 (91.3)	96.9 (93.9)	98.5 (98.6)
Redundancy	6.35 (5.6)	3.3 (2.9)	3.3 (3.1)	6.5 (6.5)
<i>I</i> / σ (<i>I</i>)	14.57 (1.93)	14.18 (1.52)	16.31 (1.57)	8.73 (2.33)
<i>R</i> _{meas}	5.9 (78.2)	4.4 (77.1)	3.8 (78.6)	13.2 (84.3)
Wilson B factor (Å ²)	30.3	30.3	32.4	43.5
Refinement				
Resolution range (Å)	43 – 1.45			43 – 2.35
No. of unique reflections	22210			5198
Final <i>R</i> _{work} / <i>R</i> _{free} (%)	17.57 / 19.95			26.80 / 30.54
<i>No. of non-H atoms</i>				
Protein	868			867
Ions	9			20
Water	97			6
Total	974			893
<i>R.m.s. deviations</i>				
Bonds (Å)	0.004			0.002
Angles (°)	0.720			0.461
<i>Average B factors (Å²)</i>				
Protein	38.7			66.8
Ions	27.1			76.3
Water	47.1			59.3
<i>Ramachandran plot</i>				
Favored regions (%)	99.06			99.06
Allowed regions (%)	0.94			0.94
Outliers (%)	0			0

1313

1314 **Table 1.** Data collection and refinement statistics.

1315

1316

Zn-ligand bond distances			
Zn site	Ligand	Bond distance (Å)	Monodentate vs Bidentate ligand
Zn1/Zn3	His21	1.92	nr
	Asp31	1.89 / 2.81	bidentate
	His92	1.99	nr
	His96	2.01	nr
Zn2/Zn4	Glu65	1.90	monodentate
	His103	2.08	nr
	His105	2.06	nr
	His107	2.04	nr

1319

1320

1321

Zn-ligand bond angles			
Zn site	Ligand 1	Ligand 2	Angle (°)
Zn1/Zn3	His21	Asp31	124.3
	His21	His92	107.4
	His21	His96	109.1
	Asp31	His92	114.2
	Asp31	His96	95.4
	His92	His96	103.8
Zn2/Zn4	Glu65	His103	111.9
	Glu65	His105	106.8
	Glu65	His107	118.5
	His103	His105	114.2
	His103	His107	104.6
	His105	His107	100.6

1322

1323

1324

1325

1326

1327 **Table 2. Zn²⁺-ligand bond distances and angles measured for the two different types of Zn-**1328 **binding sites encountered in mS100A9 crystal structure. nr: not relevant.**

1329

1330

1331

1332







1333





1334





Sample		Ca	Cr	Mn	Fe	Co	Ni	Cu	Zn
Buffer 1	ppb	151	0.061	Nd	Nd	0.122	4.760	0.554	1.787
	μ M	3.764	0.001	Nd	Nd	0.002	0.081	0.009	0.027
mS100A9	ppb	146	0.139	Nd	Nd	0.088	7.851	3.490	22.010
	μ M	3.644	0.003	Nd	Nd	0.001	0.133	0.055	0.336
	equiv./A9	0.018	1.34e-5	Nd	Nd	7.46e-6	7e-4	3e-4	0.002
Control SLRS-6									
SLRS-6	ppb	9161.5	0.260	2.218	85.513	0.059	0.612	25.76	1.960
Certified values SLRS-6	ppb	8770	0.252	2.12	84.5	0.053	0.617	24.0	1.76
	SD (ppb)	200	0.012	0.10	3.6	0.012	0.022	1.8	0.12










1335







1336 **Table 3. Metal content of purified WT mS100A9 as analyzed by ICP-MS.** Each sample was
1337 analyzed only once (averaging over 3 replicates). Metal content is given in parts per billion (ppb),
1338 in concentration (μ M), and as molar equivalents with respect to mS100A9. Nd indicates that the
1339 concentration was below detection limit and could not be determined. Certified water SLRS-6 was
1340 used as a control (both the values measured in our experiments, the certified values and the
1341 standard deviation SD on certified values are indicated for SLRS-6).


















A**B**